### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>About San Diego</td>
<td>23</td>
</tr>
<tr>
<td>Abstract Book</td>
<td>19</td>
</tr>
<tr>
<td>Advance Registration</td>
<td>21</td>
</tr>
<tr>
<td>Bookstore</td>
<td>4</td>
</tr>
<tr>
<td>Continuing Education Credit</td>
<td>4</td>
</tr>
<tr>
<td>Corporate Sponsored Symposia</td>
<td>26</td>
</tr>
<tr>
<td>Exhibit Hall Hours</td>
<td>20</td>
</tr>
<tr>
<td>Hotel Reservation Request Form</td>
<td>24</td>
</tr>
<tr>
<td>Hotels</td>
<td>25</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>3</td>
</tr>
<tr>
<td>Meeting Overview</td>
<td>20</td>
</tr>
<tr>
<td>Membership</td>
<td>30</td>
</tr>
<tr>
<td>Program Sessions</td>
<td>10</td>
</tr>
<tr>
<td>Registration Form &amp; Fees</td>
<td>22</td>
</tr>
<tr>
<td>Registration Hours</td>
<td>21</td>
</tr>
<tr>
<td>Scientific Sessions Planning Committee</td>
<td>3</td>
</tr>
<tr>
<td>Travel Services</td>
<td>23</td>
</tr>
</tbody>
</table>

### WHO SHOULD ATTEND?

All health care professionals involved in diabetes research or the delivery of diabetes care and services are encouraged to join their colleagues June 10 - 14, 2005 in San Diego, California, for the American Diabetes Association’s 65th Scientific Sessions. Physicians, researchers, nurses, dietitians, and other healthcare professionals will benefit from the comprehensive programming and stimulating atmosphere of the 65th Scientific Sessions. This year’s program includes eight theme areas, beginning on Friday, June 10 at 2:00 pm and ending at **10:00 am Tuesday, June 14**. In addition, you will find information on products and services in the Scientific Sessions extensive exhibition hall. Representatives will be available daily to provide you with the latest on products and services to improve health care delivery for patients with diabetes. Mark your calendars now for the 65th Scientific Sessions!

### IMPORTANT DATES: 65th SCIENTIFIC SESSIONS

- Last day to submit Late Breaking-Abstracts        : April 8, 2005
- Last day to request housing                      : April 20, 2005
- Last day to submit advance registration          : April 29, 2005
- Last day to cancel a conference registrant and receive a partial refund : May 14, 2005
- Last day to cancel hotel reservations with no penalty : June 1, 2005

### PROGRAM HIGHLIGHTS

- **New This Year** — The 65th Scientific Sessions program will begin with sessions in eight theme areas on Friday, June 10 at 2:00 pm and will end at **10:00 am on Tuesday, June 14**.
- **Poster Session** - All posters will be available for viewing from Saturday, June 11, through Monday, June 13.
- **State of the Art Lectures** - Due to popular demand, State of the Art Lectures will be added to many of the Oral Abstract sessions this year.

### CONTACT INFORMATION

<table>
<thead>
<tr>
<th>Contact</th>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstracts</td>
<td>Kelly Kelley</td>
<td><a href="mailto:abstracts@diabetes.org">abstracts@diabetes.org</a></td>
</tr>
<tr>
<td>Affiliate Functions</td>
<td>Felicia Price</td>
<td><a href="mailto:fprice@diabetes.org">fprice@diabetes.org</a></td>
</tr>
<tr>
<td>Corporate Sponsored Symposia</td>
<td>Sharaine Rajack</td>
<td>sr <a href="mailto:rajack@diabetes.org">rajack@diabetes.org</a></td>
</tr>
<tr>
<td>Exhibits</td>
<td>ADA Exhibit Services</td>
<td><a href="mailto:exhibits@diabetes.org">exhibits@diabetes.org</a></td>
</tr>
<tr>
<td>General Meeting Information</td>
<td>Meeting Services</td>
<td><a href="mailto:meetings@diabetes.org">meetings@diabetes.org</a> or 800-342-2383</td>
</tr>
<tr>
<td>Registration/Housing</td>
<td>Wyndham Jade</td>
<td><a href="mailto:ada@wyndhamjade.com">ada@wyndhamjade.com</a></td>
</tr>
<tr>
<td>Attendees:</td>
<td></td>
<td>1-866-268-0195 (U.S. Only), 972-349-5433 (International)</td>
</tr>
<tr>
<td>Exhibitors:</td>
<td></td>
<td>1-866-268-0196 (U.S. Only), 972-349-5434 (International)</td>
</tr>
</tbody>
</table>

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
POSTER SESSIONS AND RECEPTIONS
Posters will be displayed on Saturday, Sunday and Monday in the exhibit hall of the Convention Center. All posters will remain up for three days. Poster presenters will be scheduled to be at their poster boards to discuss their research for two hours on an assigned day and again during an evening Poster Reception on Saturday or Sunday. See page 9 for additional information.

Saturday, June 11
10:00 am - 6:00 pm  Posters on Display
12:30 pm - 2:30 pm  Poster Presenters On-site
5:00pm - 6:00 pm  Poster Session Reception and Poster Presenters On-site

Sunday, June 12
7:00 am - 7:30 pm  Posters on Display
12:00 pm - 2:00 pm  Poster Presenters On-site
6:30pm - 7:30 pm  Poster Session Reception and Poster Presenters On-site

Monday, June 13
7:00 am - 4:00 pm  Posters on Display
12:00 pm - 2:00 pm  Poster Presenters On-site

LEARNING OBJECTIVES
At the conclusion of this activity, attendees will be able to:

• Assess the latest research in the area of microvascular complications of diabetes and the implications for clinical practice.
• Assess data from recent studies focusing on pre-diabetes, insulin resistance, and the development of type 2 diabetes in children, adolescents, and adults.
• Review recent research related to women with prediabetes and diabetes, including glycemic control in the periconceptional period, treatment options during pregnancy, and mental and reproductive health.
• Explain the implications of recent research related to the genetics of diabetes, including the fetal origins hypothesis and gene-mapping.
• Discuss the clinical implications of recent research in the immunology of diabetes on islet and pancreas transplantation.
• Describe the role of lipids, inflammation, and insulin resistance in the development and progression of cardiovascular disease.
• Employ various behavioral medicine, nutrition, and health education techniques in the treatment of diabetes, including CQI, medical nutrition therapy, obesity treatment, and family care.
• Evaluate current strategies related to the treatment and prevention of obesity, including food intake and body weight, metabolic syndrome, gastric bypass, genetics and the environment, leptin biology, and nutrient modulation.
• Explain recent research related to the role and function of the beta-cell in islet biology and insulin secretion.
• Assess the social, medical, and educational issues of diabetes through the lifecycle and review strategies for improving clinical outcomes.
• Review recent studies related to detection and management of macrovascular disease in patients with type 1 and type 2 diabetes, including children and adolescents.
ACCREDITATION AND CONTINUING EDUCATION CREDIT

Physicians: The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Diabetes Association designates this continuing medical education activity for a maximum of 29.0 hours in Category 1 Credit toward the Physician’s Recognition Award of the American Medical Association. Each physician should claim only those hours of credit he/she spent in the educational activity.

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA category 1 credit.

Nurses: The American Diabetes Association is approved as a provider of continuing education in nursing by the Virginia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. The American Diabetes Association is located at 1701 N. Beauregard Street, Alexandria, VA 22311. VNA Provider No. 04-03-02.

This education activity is approved by the Virginia Nurses Association (VNA) which is accredited by the American Nurses Credentialing Center’s Commission on Accreditation as an approver of continuing education in nursing for a maximum of 35.0 VNA contact hours. The VNA is located at 7113 Three Chopt Road, Suite 204, Richmond, VA 23226.

The American Diabetes Association is a provider approved by the California Board of Registered Nursing, Provider No. CEP-12196, for a maximum of 29.0 contact hours.

Certified Diabetes Educators: The American Diabetes Association is an approved continuing education provider by the National Certification Board of Diabetes Educators (NCBDE). Therefore, attendance at this activity can be used toward fulfilling CDE recertification requirements.

Dietitians: This activity has been approved by the Commission on Dietetic Registration (CDR) for a maximum of 29.0 hours of continuing professional education credit.

Podiatrists: The Association has been granted affiliate sponsorship from the American Podiatric Medical Association to offer continuing education credits to podiatrists for this activity.

Pharmacists: The American Diabetes Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides up to 29.0 contact hours of continuing pharmacy education credit. The ACPE program number is 239-000-05-004-C01. Each pharmacist should claim only those hours of credit that he/she spent in the education activity.

Visit us in the San Diego Convention Center during the Scientific Session!

ADA BOOKSTORE
Save 25% on all titles!

Featuring essential resources for professionals and their patients:
- Nutrition/Meal Planning
- Educational Resources
- Clinical Education
- PowerPoint Presentations
- Best Sellers
- Cookbooks
- Self Care

BOOKSTORE HOURS:
THURSDAY ..........4:00 p.m. – 8:00 p.m.
FRIDAY..............8:00 a.m. – 6:00 p.m.
SATURDAY.........7:00 a.m. – 5:00 p.m.
SUNDAY..........7:00 a.m. – 5:00 p.m.
MONDAY.............7:00 a.m. – 5:00 p.m.
TUESDAY............7:00 a.m. – 12:30 p.m.
## DAY-AT-A-GLANCE

**FRIDAY, JUNE 10, 2005**

### Pre-Conference Symposia

<table>
<thead>
<tr>
<th>Time</th>
<th>Symposia</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 - 12:45</td>
<td>American Society of Transplantation Symposium: Clinical Advances in Transplantation for the Diabetologist — 21st Century State of the Art</td>
</tr>
<tr>
<td>8:30 - 12:30</td>
<td>Diabetes in the Latino Population: A Case-Based Approach to Optimal Management</td>
</tr>
<tr>
<td>10:00 - 10:45</td>
<td>First-Time Attendee Orientation</td>
</tr>
</tbody>
</table>

### 2:00 - 4:00

<table>
<thead>
<tr>
<th>Islet Biology/Insulin Secretion</th>
<th>Insulin Signaling/Insulin Action</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, Exercise</th>
<th>Acute and Chronic Complications</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Clinical Diabetes/Therapeutics (Includes Pediatrics &amp; Pregnancy)</th>
<th>Integrated Physiology or Obesity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stressing Out the Beta-Cell: Mechanisms for Death and Dysfunction</td>
<td></td>
<td>Nephrons, Diabetes, Nutrition, and the 2005 National Kidney Foundation Guidelines — Enhancing Care Coordination</td>
<td></td>
<td>Functional Genomic Approaches to Diabetes Mellitus</td>
<td>Following the Anti-Islet Immune Response in Vivo</td>
<td>Forms of Secondary Diabetes Insulin Pumps and Diabetes</td>
<td>Role of Inflammation in the Pathogenesis of Type 2 Diabetes</td>
</tr>
</tbody>
</table>

### 4:15 - 6:15

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Membrane Trafficking — The Ins and Outs of the Beta-Cell</td>
<td></td>
<td></td>
<td>MRS vs. PET — How Can We Use These Techniques to Help Us Understand the Brain?</td>
<td>The Metabolic Syndrome 2005 — Mechanisms and Consequences</td>
<td></td>
<td>Moving On Up — Diabetes Through Childhood, Adolescence and Adulthood</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00-10:00</td>
<td><strong>Symposium Regeneration — Regenerating Beta-Cells</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>National Diabetes Education Program</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposia Epidemiology of Childhood Diabetes — What’s New and What’s Needed?</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposia Lipid Targets for CHD in Diabetes</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium Endothelial Dysfunction — The Cart or the Horse for Insulin Resistance?</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Current Issues Does Peptide YY Regulate Food Intake and Body Weight?</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-12:15</td>
<td><strong>Symposium Mechanisms of Insulin Resistance</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium Women with Diabetes Throughout the Lifecycle</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium IDF/ADA Symposium — World Diabetes Day 2005 — Focus on Foot Complications</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium Islet Structure and Function in Type 1 Diabetes</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium Treatment of Non-Traditional Cardiovascular Risk Factors — Which Cardiovascular Risk Factors Should We Measure and Why?</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Current Issues Is there a Future Cure for Diabetes through Molecular Engineering?</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-2:30</td>
<td>General Poster Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Council Discussions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary — NIDDK Obesity Initiative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary — Human Genes: Diabetes and Obesity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45-4:45</td>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium Fanning the Flames of Insulin Resistance</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium The Role of the Family in Diabetes Care</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium EASD/ADA Symposium Diabetic Neuropathy — Clinical and Experimental Progress</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Symposium New Insulins</strong> Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00-6:00</td>
<td>Poster Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 -12:00</td>
<td>ADA Celebration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00-8:45</td>
<td><strong>Symposium</strong>&lt;br&gt;Transcriptional&lt;br&gt;Regulation of the Beto-Cell Phenotype</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Social and Health Consequences of Obesity&lt;br&gt;<strong>Symposia</strong>&lt;br&gt;Genomics and Stem Cells in the Retina — From Bench to Bed&lt;br&gt;Hypoglycemia in the Brain — What does the Brain do when the Cupboard is Bare?&lt;br&gt;<strong>Kelly West Lecture</strong>&lt;br&gt;9:00 - 9:45&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Islet Transplantation: Improving the Process — Overcoming Rejection</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Diagnosis and Management of Sexual Dysfunction in Diabetes&lt;br&gt;Management of the Hospitalized Hyperglycemic Patient — Insulin&lt;br&gt;What is Gestational Diabetes? Does Treatment Make A Difference?&lt;br&gt;(Includes Norbert Freinkel Lecture)</td>
<td><strong>Symposium</strong>&lt;br&gt;New Developments in Leptin Biology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00-10:00</td>
<td><strong>Symposium</strong>&lt;br&gt;Transcriptional&lt;br&gt;Regulation of the Beto-Cell Phenotype</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Social and Health Consequences of Obesity&lt;br&gt;<strong>Symposia</strong>&lt;br&gt;Genomics and Stem Cells in the Retina — From Bench to Bed&lt;br&gt;Hypoglycemia in the Brain — What does the Brain do when the Cupboard is Bare?&lt;br&gt;<strong>Kelly West Lecture</strong>&lt;br&gt;9:00 - 9:45&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Islet Transplantation: Improving the Process — Overcoming Rejection</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Diagnosis and Management of Sexual Dysfunction in Diabetes&lt;br&gt;Management of the Hospitalized Hyperglycemic Patient — Insulin&lt;br&gt;What is Gestational Diabetes? Does Treatment Make A Difference?&lt;br&gt;(Includes Norbert Freinkel Lecture)</td>
<td><strong>Symposium</strong>&lt;br&gt;New Developments in Leptin Biology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td><strong>President’s Address and Banting Lecture</strong>&lt;br&gt;General Poster Session&lt;br&gt;Council Discussions</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Management of the Hospitalized Hyperglycemic Patient — Medical Nutrition Therapy&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Impact of Diabetes on the Vascular Wall — New Cellular Targets for Treatment&lt;br&gt;(Includes Edwin Bierman Lecture)&lt;br&gt;<strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Controversies in the Use of Oral Agents in Diabetes Management&lt;br&gt;Glycemic Control in the Periconceptional Period — Sweet Success or Sour Grapes?&lt;br&gt;Late Breaking Clinical Trials</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Adiponectin — Still in the Sun&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Adiponectin — Still in the Sun</td>
<td><strong>Symposium</strong>&lt;br&gt;New Developments in Leptin Biology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00-4:00</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Management of the Hospitalized Hyperglycemic Patient — Medical Nutrition Therapy&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Impact of Diabetes on the Vascular Wall — New Cellular Targets for Treatment&lt;br&gt;(Includes Edwin Bierman Lecture)&lt;br&gt;<strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Controversies in the Use of Oral Agents in Diabetes Management&lt;br&gt;Glycemic Control in the Periconceptional Period — Sweet Success or Sour Grapes?&lt;br&gt;Late Breaking Clinical Trials</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Adiponectin — Still in the Sun&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Adiponectin — Still in the Sun</td>
<td><strong>Symposium</strong>&lt;br&gt;Driving and Hypoglycemia — Risk Assessment and Potential Approaches&lt;br&gt;(Includes Council on Behavioral Medicine and Psychology Distinguished Contributions Lecture)</td>
<td><strong>Symposium</strong>&lt;br&gt;Talk Before You Act — Organ Cross-Talk in Insulin Action</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:15-6:15</td>
<td><strong>Symposium</strong>&lt;br&gt;Transcriptional Effects in Insulin Signaling&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Continuous Quality Improvement and its Application in Diabetes Self-Management Training Programs&lt;br&gt;Driving and Hypoglycemia — Risk Assessment and Potential Approaches</td>
<td><strong>Oral Presentations</strong>&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;A Life Course Approach to Diabetes Epidemiology&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Islet Transplantation: Improving the Process — The Islets&lt;br&gt;<strong>Symposium</strong>&lt;br&gt;Is Insulin Resistance a Relevant Treatment Target?&lt;br&gt;<strong>Oral Presentations</strong>&lt;br&gt;(Includes Council on Behavioral Medicine and Psychology Distinguished Contributions Lecture)</td>
<td><strong>Symposium</strong>&lt;br&gt;Talk Before You Act — Organ Cross-Talk in Insulin Action</td>
<td><strong>Symposium</strong>&lt;br&gt;Talk Before You Act — Organ Cross-Talk in Insulin Action</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30-7:30</td>
<td><strong>Poster Reception</strong></td>
<td><strong>Poster Reception</strong></td>
<td><strong>Poster Reception</strong></td>
<td><strong>Poster Reception</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Islet Biology/Insulin Secretion</td>
<td>Insulin Signaling/Insulin Action</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, Exercise</td>
<td>Acute and Chronic Complications</td>
<td>Epidemiology/Genetics</td>
<td>Immunology/Transplantation</td>
<td>Clinical Diabetes/Therapeutics (Includes Pediatrics &amp; Pregnancy)</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00-10:00</td>
<td>Symposium Developmental Biology — The Beginnings of the Pancreas</td>
<td>Oral Presentations</td>
<td>President, Health Care &amp; Education</td>
<td>Symposium Animal Models of Wound Healing in Diabetes</td>
<td>Symposium Epidemic of Impaired Fasting Glycemia — Is it Real and What Do We Do?</td>
<td>Current Issues Clinical and Pre-Clinical Updates</td>
<td>Symposium Future of PPAR Agonists</td>
</tr>
<tr>
<td>10:15-11:45</td>
<td>Scientific Achievement Awards Presentations and Outstanding Scientific Achievement Awards Lecture</td>
<td>General Poster Session</td>
<td>General Poster Session</td>
<td>General Poster Session</td>
<td>General Poster Session</td>
<td>General Poster Session</td>
<td>General Poster Session</td>
</tr>
<tr>
<td>2:15-4:15</td>
<td>Oral Presentations</td>
<td>Symposium Motoring Along the mTOR Pathway</td>
<td>Oral Presentations</td>
<td>Symposium Is There a Role for Glucose in Diabetic Cardiovascular Disease?</td>
<td>Symposium Case Studies: Evolving Patterns of Diabetic Infection (Includes Roger Pecoraro Lecture)</td>
<td>Oral Presentations</td>
<td>Case Studies</td>
</tr>
</tbody>
</table>
## GENERAL POSTER SESSION CATEGORIES

Poster presenters will be available at their boards for questions as listed on the above schedule during the lunch hours. Refer to the Day-At-A-Glance for exact times each day. A schedule for the Poster Receptions will be available in the Final Program.

### Saturday, June 11
- Complications, Hypoglycemia
- Complications, Macrovascular
- Complications, Neuropathy
- Diabetes Education
- Genetics
- Insulin Action
- Nutrition - Clinical
- Pediatrics
- Psychosocial/Behavioral Medicine

### Sunday, June 12
- Clinical Therapeutics/New Technology
  - Pharmacologic Treatment of Diabetes or its Complications
- Epidemiology
- Foot Care/Lower Extremities
- Health Care Delivery/Economics
- Immunology
- Integrated Physiology
- Pregnancy
- Signal Transduction (Not Insulin Action)

### Monday, June 13
- Clinical Therapeutics/New Technology
  - Glucose Monitoring and Sensing
- Clinical Therapeutics/New Technology
  - Insulin Delivery Systems
- Clinical Therapeutics/New Technology
  - Other Drug Delivery Systems
- Clinical Therapeutics/New Technology
  - Treatment of Insulin Resistance
- Complications, Nephropathy
- Complications, Ocular
- Diabetic Dyslipidemia
- Exercise
- Gene Expression Chips and Microarrays
- Islet Biology
- Obesity
- Transplantation
PROGRAM
FRIDAY, JUNE 10
2:00 PM - 4:00 PM

Current Issues
- Following the Anti-Islet Immune Response in Vivo
  T-Cell Assays for Following Anti-Beta Cell Immunity
  Mark Peakman, MD, PhD
  In Vivo Imaging of Transplanted Islets
  Alvin C. Powers
  Molecular Imaging of Pancreatic Islets
  Anna V. Moore, PhD
  In Vivo Analysis of Immune Response
  Qizhi Tang, PhD

Symposia
- Forms of Secondary Diabetes
  Diabetes in HIV-Infected Patients
  Colleen M. Hadigan, MD
  Diabetes in Patients on Atypical Antipsychotics
  John W. Newcomer, MD
  Diabetes in Patients with Liver Disease
  James H. Lewis, MD

- Functional Genomic Approaches to Diabetes Mellitus
  The Diabetes Genome Anatomy Project
  Michael P. Czech, PhD
  The Beta-Cell Consortium
  Klaus H. Kaestner, PhD
  Computational and Integrative Genomics
  Haiyuan Yu, PhD
  Genetic and Genomic Approaches to Human Diabetes
  Yamsi K. Mootha, MD

- Insulin Pumps and Diabetes
  Smart Pumps — Gimmicks or Real Improvement?
  Howard A. Wolpert, MD
  Pumps in Type 2 Diabetes — Use or Abuse?
  Bruce Bode, MD
  Pumps Versus Analog MDI
  David S. Schade, MD
  Pumping in Children and Adolescents — Where Are We Now?
  Bruce A. Buckingham, MD

- Nephrons, Diabetes, Nutrition, and the 2005 National Kidney Foundation Guidelines — Enhancing Care Coordination
  Diabetic Kidney Disease — Reviewing the Science
  TBD
  2005 NKF Guidelines — Nutrition Recommendations
  TBD
  Practical Implementation — Facilitating Medical Care: Linking Endocrinology and Nephrology
  Mark E. Molitch, MD
  Practical Implementation — Facilitating Nutritional Care
  Patricia A. Weber, MS, RD, CDE, LDN

- Role of Inflammation in the Pathogenesis of Type 2 Diabetes
  Where Do the Inflammatory Factors Come From?
  John N. Fain, PhD
  Is IL-6 a Good Guy?
  Robert A. Mooney, PhD
  Is IL-6 a Bad Actor?
  Bente Klarlund Pedersen, MD
  From Steatosis to NASH
  Samuel Klein, MD

- Stressing Out the Beta-Cell: Mechanisms for Death and Dysfunction
  Oxidative Stress, Glucose Toxicity, and Type 2 Diabetes
  R. Paul Robertson, MD
  ER Stress
  Randal J. Kaufman, PhD
  Amyloid Stress
  Rebecca Hull, PhD

Inflammatory Stress
Marc Y. Donath, MD

Oral Abstract Presentations
4:15 PM - 6:15 PM

Current Issues
- Moving On Up — Diabetes Through Childhood, Adolescence and Adulthood
  Educational — From Home to School
  Monica M. DiNardo, MSN, CRNP, CDE
  Social/Psychological — From Dependence to Independence
  Mark Payrot, PhD
  Medical — From Pediatrics to Internal Medicine
  Rebecca Lipton, PhD

- MRS vs. PET — How Can we Use these Techniques to Help us Understand the Brain?
  MRS Methods to Study the Brain and its Limitations
  Rolf Gruetter, PhD
  PET Methods to Study the Brain and its Limitations
  William J. Powers, MD

- The Role of Intensive Insulin Therapy for Acute Myocardial Infarction
  TBD

Symposia
- Immune Mechanisms Underlying Type 1 Diabetes
  Innate Immunity and Toll Receptors
  Li Wen, MD, PhD
  Regulatory T-Cells
  Steven F. Ziegler, PhD
  Dendritic Cells Contribution to the Development or Inhibition of Type 1 Diabetes
  S. Brian Wilson, MD, PhD
  MHC Class 1 Restricted Antigens Targeted by CD8 T-Cells Essential to the Initiation of Type 1 Diabetes
  Teresa DiLorenzo, PhD
Membrane Trafficking — The Ins and Outs of the Beta-Cell
The Nuts and Bolts — A Proteomic Approach to the Regulated Secretory Pathway
John J.M. Bergeron, DPhil
The Way Out — Assembly of the Secretory Synapse
Craig C. Garner, PhD
The Way Back In — Endocytosis in the Regulated Pathway
Marilyn G. Farquhar, PhD
Autophagy — The One-Way Ticket
Ana Maria Cuervo, MD, PhD

The Metabolic Syndrome 2005 — Mechanisms and Consequences
The Physiologic Basis for the Metabolic Syndrome
Eleuterio Ferrannini, MD
What is the Best Way to Predict Cardiovascular Disease in People with Diabetes?
Michael P. Stern, MD
Modeling the Metabolic Syndrome — New Insights
David M. Eddy, MD, PhD
Evidence for Benefit from Lifestyle Interventions on Metabolic Syndrome
Pirjo Ilanne-Parikka, MD

Oral Abstract Presentations
SATURDAY, JUNE 11
8:00 AM - 10:00 AM
Current Issues

Does Peptide YY Regulate Food Intake and Body Weight?
Yes
Stephen R. Bloom, MD

No
Matthias H. Tschoep, MD

Symposia

Endothelial Dysfunction — The Cart or the Horse for Insulin Resistance?
Endothelial Cell Activation and Dysfunction
Ishwarlal Jialal, MD, PhD

Endothelial Dysfunction and Risk for Diabetes and CVD
JoAnn Elisabeth Manson, MD, DrPH

Endothelium as an Insulin-sensitive Tissue — Implications for Vascular-sensitive Tissue —
Implications for Vascular-sensitivit"Tissue —
Francis Kim, MD

Nitric Oxide and Insulin Action — When a Good Thing Becomes Too Much of a Good Thing
André Marette, PhD

Epidemiology of Childhood Diabetes — What’s New and What’s Needed?
Diabetes Registries — Have We Met the Challenge of Estimating Incidence and Prevalence?
Ingrid M. Libman, MD, PhD

Is it Type 1 or is it Type 2? Evolving Methods and Estimates of Disease Occurrence by Type
Dorothy J. Becker, MD

The Accelerator Hypothesis — A Unifying Paradigm for Diabetes Type?
Terence J. Wilkin, MD

Screening for Diabetes in High Risk Youth — Is there Evidence for Action?
David J. Pettitt, MD

Large-Scale Genomic Science in Genetic Studies of Diabetes
Dense SNP Typing for Fine-Mapping
Alan R. Shuldiner, MD

Deep Resequencing — An Alternative or Complement to Dense SNP Typing?
Anna DiRienzo, PhD

Genome-Wide Association Studies Using a Location or Gene-Based Strategy
Nancy J. Cox, PhD

Lipid Targets for CHD in Diabetes
LDL Goals in DM — How Low and In Whom?
Neil J. Stone, MD

What Should be the Secondary Targets — Low HDL Cholesterol
TBD

What Should be the Secondary Targets — High Triglycerides
TBD

Metformin in Pregnancy — Is it Safe? Does it Work?
Cellular and Metabolic Actions of Metformin — Applications to its use During Pregnancy
Clifford J. Bailey, PhD, FRCP, FRCPath

Determining Teratogenesis of a Drug, with Special Reference to Metformin
Gerald G. Briggs, B.Pharm

Metformin in the First Trimester and the Prevention of Gestational Diabetes
Charles J. Glueck, MD

Metformin — A Logical Treatment for Type 2 Diabetes during Pregnancy?
Janet A. Rowan, MD

National Diabetes Education Program (NDEP): Clinical Focus — Using the National Diabetes Education Program to Improve your Practice, Patient Outcomes, and Maybe Even your Bottom Line
Resources to Help Improve Outcomes in Adults and Children with Diabetes
James R. Gavin, III, MD

Web-Based Resources to Improve Care for People with Diabetes and People at Risk — and Maybe Even your Bottom Line
Lawrence Blonde, MD

Small Steps, Big Rewards — Your GAMEPLAN for Preventing Type 2 Diabetes
Charles M. Clark, Jr., MD

Regeneration — Regenerating Beta-Cells
JAK-STAT Signaling in Beta-Cells
Jens H. Nielsen, PhD

Adult Pancreatic Stem Cells — Where are we?
Derek van der Kooy, PhD

AKTing out Signaling Pathways in Islet Expansion
Anil Bhushan, PhD

Oral Abstract Presentations
10:15 AM - 12:15 PM

Current Issues

- Genetics or Environment – Which Plays a Greater Role in Obesity?
  - Genetics
    - Claude Bouchard, PhD
  - Environment
    - James O. Hill, PhD

- Is there a Future Cure for Diabetes through Molecular Engineering?
    - Lawrence C. B. Chan, MD, DSc
  - Ex Vivo Cell Production
    - David Klonoff, MD

Symposia

- IDF/ADA Symposium – World Diabetes Day 2005 – Focus on Foot Complications
  - The Global View of the Diabetic Foot
    - Andrew J.M. Boulton, MD
  - Foot Disease in Developing Countries
    - Zulfiqari G. Abbas, MBBS, MMed, DTM&H
  - Consensus Summary – International Working Group on the Diabetic Foot
    - Karel Bakker, MD, PhD
  - TASC Guidelines for Peripheral Vascular Disease
    - George Andros, MD

- Islet Structure and Function in Type 1 Diabetes
  - The Pancreas in the Patient with Type 1 Diabetes
    - Alan Foulis, MD
  - Enterovirus Infection of Pancreatic Islets
    - Francesco Dotta, MD
  - Pancreatic Biopsy/Fulminant Diabetes
    - Toshiaki Hanafusa, MD, PhD
  - Islet Survival/Function in Patients with Long-standing Type 1 Diabetes
    - Peter C. Butler, MD

- Mechanisms of Insulin Resistance
  - ER Stress in Insulin Resistance
    - Gokhan S. Hotamisligil, MD, PhD
  - Macrophages and Insulin Resistance
    - Anthony W. Ferrante, MD, PhD
  - Nutrient Control of Glucose Homeostasis Through the PGC-1α Pathway
    - Pere Puigserver, PhD
  - Leptin-Mediated Inflammation
    - Giuseppe Matarese, MD, PhD

- Treatment of Non-Traditional Cardiovascular Risk Factors – Which Cardiovascular Risk Factors Should We Measure and Why?
  - C-Reactive Protein
    - TBD
  - Lipid Particle Size - If and When?
    - TBD
  - Calcium Scores
    - Lewis H. Kuller, MD, DrPH

- Women with Diabetes Throughout the Lifecycle
  - PCOS/Gestational Diabetes
    - Andrea E. Dunlap, MD
  - Preconception Counseling – Type 2 in Pregnancy – Oral Agents Pros/Cons
    - Julie M. Slocum, RN, MS, CDE
  - PMS and Diabetes
    - Laura B. Hershman, MSc, APRN, BC-ADM, CDE
  - Menopause and Diabetes – HRT or Not
    - Laura B. Hieronymus, MSEd, APRN, BC-ADM, CDE

Oral Abstract Presentations

12:30 PM - 2:30 PM

General Poster Session
See categories listed on page 9.

12:30 PM - 1:45 PM

Council Discussion Sessions

- Council on Clinical Endocrinology, Health Care Delivery & Public Health
  - TBD

- Council on Epidemiology and Statistics
  - Impact of HIPAA Regulation on Diabetes Epidemiology Research: Observational Studies and Clinical Trials
    - William H. Herman, MD, MPH

- Council on Exercise
  - Physical Activity and Diabetes Prevention: How do We Make it Work?
    - Andrea M. Kriska, PhD

- Council on Foot Care
  - Old and New Treatment Options for Painful Neuropathy
    - Roy Freeman, MD and Andrew J.M. Boulton, MD

- Council on Immunology, Immunogenetics and Transplantation
  - What is the Future for Pancreatic Islet Transplantation?
    - David M. Harlan, MD

- Council on Molecular, Cellular and Biomedical Aspects of Diabetes
  - Ask Questions and Learn about ADA – Sponsored Research
    - TBD

2:45 PM - 3:30 PM

Plenary

- The NIDDK/NIH Agenda for Support of Research on Diabetes and Obesity
  - Allen M. Spiegel, MD

3:45 PM - 4:30 PM

Plenary

- Human Obesity and Insulin Resistance – Lessons from the Extremes
  - Stephen O’Rahilly, MD

2:45 PM - 4:45 PM

Case Studies

- Consequences of Having Too Much or Too Little Ghrelin
  - Obesity, Diabetes, and Hypothyroidism in a Patient with a Functional, Malignant Ghrelinoma
    - Apostolos V. Tsolakis, MD
Does Excessive Ghrelin Cause Weight Gain and/or Diabetes?
Kenji Kangawa, PhD

Does Ghrelin Deficiency Cause Weight Loss and/or Improved Glucose Tolerance?
Katherine E. Wortley, PhD

Symposia

EASD/ADA Symposium — Diabetic Neuropathy — Clinical and Experimental Progress
Diabetic Neuropathy — Results from the UKPDS
Rury R. Holman, MD
Signaling and Diabetic Neuropathy
Angelika Bierhaus, PhD
Oxidative Stress, PARP, and Neuropathy
Szabó Csaba, MD, PhD
Neuro-Glia Interaction — Possible Implications for Diabetic Neuropathy
Klaus-Armin Nave, PhD

Fanning the Flames of Insulin Resistance
The Inflammatory Master Switch NF-κB in Fat and Liver Mediates Insulin Resistance and Metabolic Syndrome
Steven E. Shoelson, MD, PhD
Toll Signaling
Bruce Beutler, MD
SOCS Proteins in Insulin Resistance
Paul B. Rothman, MD
PPARs and Inflammation
Ron E. Law, PhD

New Insulins
Basal Analogs and Beyond
Malcolm Nattrass, MD, PhD
Are All of the Rapid Acting Analogs the Same?
Tim Heise, MD
Should We Hold Our Breath for Inhaled Insulin?
Jay Skyler, MD
Are Premixed Insulins More than Just a Compromise?
Philip Raskin, CDE, MD

The Role of the Family in Diabetes Care
Childhood
Jill Weissberg-Benchell, PhD
Adolescence
Michael A. Harris, PhD
Working Age Adult
Lawrence Fisher, PhD
Elderly
Medha N. Munshi, MD

Oral Abstract Presentations
5:00 PM - 6:00 PM
Poster Reception
8:30 PM - 12:00 AM
ADA Celebration
SUNDAY, JUNE 12, 2005
8:00 AM - 8:45 AM
Plenary
Politics of Food
Marion Nestle, PhD, MPH

8:00 AM - 10:00 AM
Symposia
Diagnosis and Management of Sexual Dysfunction in Diabetes
Hypogonadism in Diabetes
TBD
Erectile Dysfunction
TBD
Women
Lois Jovanovic, MD

Genomics and Stem Cells in the Retina — From Bench to Bed
Genetics in Fish and Mice to Study Vessels and Nerves
Nonica Autiero, PhD
Identification of Novel Genes Involved in Endothelial Cell Biology and Angiogenesis
Roy Bicknell, PhD
Gene Profiling of the Diabetic Retina
Anand Swaroop, PhD
Stem Cells and the Retina
Martin Friedlander, MD, PhD

Hypoglycemia in the Brain — What does the Brain do When the Cupboard is Bare?
Neural Glia Interactions in the Regulation of Brain Energy Metabolism
Gerald A. Dienel, PhD
MCT Transporters and the use of Alternative Fuels in Hypoglycemia
Susan J. Vannucci, PhD
Maybe the Cupboard is not Bare After All — A Role for Brain Glycogen?
Gulin Oz, PhD
The Effect of Hypoglycemia on Brain Stress Circuitry
Dianne Lattemann, PhD

Islet Transplantation — Improving the Process — Overcoming Rejection
Current Success Rate of Islet Transplantation
Edmond Ryan, MD
Will Hematopoietic Chimerism Promote Tolerance, and/or Make New Beta Cells?
Dale L. Greiner, PhD
Novel Tolerance Promoting Regimens: “Power Mix”
Terry B. Strom, MD
Update on Strategies Employing Costimulatory Pathway Modifiers
Norma Sue Kenyon, PhD

Management of the Hospitalized Hyperglycemic Patient — Insulin
Pre- and Perioperative Period
Anthony Furnary, MD
Insulin in the ICU
Greet Van den Berghe, MD, PhD
Floating to the Floor — Insulin Infusions on the Ward
Irl B. Hirsch, MD
Subcutaneous Insulin Management
Susan S. Braithwaite, MD
New Developments in Leptin Biology
New Insights into Sites of Leptin Action and Roles of CNS Leptin Signaling in Peripheral Insulin Sensitivity
Greg Morton, PhD
Additive and Synergistic Interactions of Leptin Sensitive Neurons
Streamson Chua, MD, PhD
Leptin Treatment in Humans to Maintain Weight Loss Achieved by Traditional Means
Michael Rosenbaum, MD
The Role of Leptin Therapy in Low Leptin States
Christos S. Mantzoros, MD

Social and Health Consequences of Obesity
Obesity from a Social Perspective
Kathryn E. Henderson, PhD
Obesity from the Family Perspective
Mary E. Larkin, RN, BSN
Prevention of Type 2 Diabetes in Youth
Sheri Colberg-Ochs, PhD
“Bright Bodies” — An Innovative Weight Management Program for Overweight Youth
Mary Savoye, RD, CDN, CDE

Transcriptional Regulation of the Beta-Cell Phenotype
Regulation of Insulin Gene Expression — Before and after the Secondary Transition
Michael S. German, MD
HNF Transcription Networks
Duncan Odom, PhD
Chromatin Remodeling — Unwinding the Way to Transcription
Raghavendra Mirmira, MD, PhD
DNA Begets RNA Begets DNA (micro RNA)
Markus Stoffel, MD

What is Gestational Diabetes? Does Treatment Make a Difference? (Includes Norbert Freinkel Lecture)
Is Insulin Resistance during Pregnancy Different Between Women with Normal Glucose Tolerance and Those Who have Gestational Diabetes?
Patrick M. Catalano, MD
Is Gestational Diabetes Really a Disease of Pregnancy? A View from the Pancreatic Beta-Cell
Thomas A. Buchanan, MD, PhD, CDE
Do Interventions for Glucose Intolerance during Pregnancy make a Difference in Clinical Outcomes? — The ACHOIS Study
Caroline A. Crowther, MB, ChB
Norbert Freinkel Lecture: Gestational Diabetes Mellitus — What Have I (We) Learned in 30 Years?
Steven G. Gabb, MD

Oral Abstract Presentations
9:00 AM - 9:45 AM
Kelly West Lecture
Marian J. Rewers, MD, PhD

10:15 AM - 11:45 AM
President’s Address
Alan D. Cherrington, PhD

Bantering Lecture
Jeffrey S. Flier, MD

12:00 PM - 2:00 PM
General Poster Session
See categories listed on page 9.

12:30 PM - 1:45 PM
Council Discussion Sessions
Council on Behavioral Medicine & Psychology
Translating Proven Behavioral Interventions into Clinical Practice
Daniel J. Cox, PhD and Deborah Young-Hyman, PhD

Council on Education
Using Diplomacy to Get the Most for Your Patients
Bill Polonsky, PhD

Council on Complications
Genetics of Atherosclerosis
Stephen S. Rich, PhD

Council on Diabetes in Youth
Type 2 Diabetes and Obesity in Children and Adolescents
Larry A. Fox, MD

Council on Nutritional Science and Metabolism
Make the Link Between Nutrition Research and Clinical Practice
Elizabeth Mayer-Davis, MS, PhD, RD

Symposia
Adiponectin - Still in the Sun
Regulation of Adiponectin Receptor Expression in Human Muscle
Eric Ravussin, PhD
Regulation of Adiponectin Production and Circulating Levels
Peter J. Havel, DVM, PhD
Role of Adiponectin in Energy Homeostasis
Rexford S. Ahima, MD, PhD
Human Adiponectin Levels Predict Future Diabetes and Cardiovascular Risk
Antonio Tataranni, MD

Controversies in the Use of Oral Agents in Diabetes Management
Do Sulfonylureas Increase Cardiovascular Toxicity?
Harold Lebovitz, MD
Weight Gain with TZDs - Risk vs. Benefits
John B. Buse, MD, PhD
Should Combination Therapy be the First Therapy?
David S. Bell, MD
An Evidence-based Approach to Using Oral Agents
Michael P. Pignone, MD, MPH
Genetic Basis of Diabetes — The Role of the Beta-Cell

Genetic Susceptibility to Beta Cell Death and Dysfunction in Type 2 Diabetes Independent of Insulin Resistance
Kenneth S. Polonsky, MD
Beta-Cell Gene Mapping — IAPP, Oxidative Stress and Diabetes
Kathryn Haskins, PhD
Mathematical Modeling of Type 1 and Type 2 Diabetes — How Does this Help Us in Identifying Beta Cell Susceptibility Genes?
Xujing Wang, PhD
Predicting Type 2 Diabetes in Women Who had GDM — The Beta Gene Project
Richard M. Watanabe, PhD

Glycemic Control in the Periconceptional Period — Sweet Success or Sour Grapes?
Malformations and Gene Variants in Pregnancies Complicated by Diabetes
Mary R. Loeken, PhD
Is Glucose a Teratogen, a Co-Teratogen, or a Teratogen Surrogate?
Ulf Eriksson, MD, PhD
Preconception Care in the United States
Menachem Miodovnik, MD
Preconception Care in Denmark
Peter Damm, MD

Impact of Diabetes on the Vascular Wall — New Cellular Targets for Treatment (Includes Edwin Bierman Lecture)
Edwin Bierman Lecture: Dyslipidemia in Metabolic Syndrome and Diabetes
John D. Brunzell, MD
Effects of Oxidized Lipids in Vascular Smooth Muscle Cells
Rana Natarajan, PhD
Chemokines and Macrophages
Christopher K. Glass, MD, PhD
Role of Extracellular Matrix in Diabetic Nephropathy
Vincent C. Hascall, PhD

Late Breaking Clinical Trials

Management of the Hospitalized Hyperglycemic Patient — Medical Nutrition Therapy
Considerations for Nutrition Intervention — To Feed or Not To Feed?
TBD
Best Choices in Nutrition Intervention
Pam Charney, MS, RD, CDE
Best Choices in Nutrition Intervention
TBD

Oral Abstract Presentations

4:15 PM - 6:15 PM
Symposia

A Life Course Approach to Diabetes Epidemiology
The Fetal Origins Hypothesis — Epidemiological Evidence
David Barker, BSc, PhD, MD
Pathways of the Fetal Origins Hypothesis — Insulin Resistance or Insulin Secretion?
Dana Dabelea, MD, PhD
Potential Mechanisms — Genes or Environment?
David Dunger, MD
Life Course Epidemiology of Diabetes Beyond the Fetal Origins — The Role of Obesity in Childhood and Beyond
Stephen R. Daniels, MD, PhD

Continuous Quality Improvement and its Application in Diabetes Self Management Training Programs
Principles of CQI in Diabetes Self-Management Training Programs
Joan K. Bardsley, RN, MBA, CDE
CQI Processes in Behavioral and Clinical Interventions
Karen N. Harriman, RN, MSN, CFNP, CDE
The Use of CQI to Improve DSMT Program Outcomes
Terry A. Lumber, CNS, MSN, CDE, BC-ADM
ADA Education Recognition Program
Blanche M. Bronzini, RN, MPH, CDE

Driving and Hypoglycemia — Risk Assessment and Potential Approaches (Includes Council on Behavioral Medicine and Psychology Distinguished Contributions Lecture)
The Influence of Type 1 Diabetes on Driving Over the Life Span
Thomas J. Songer, PhD
Hypoglycemia and Driving in People with Insulin Treated Diabetes — Adherence to Recommendations
Brian M. Frier, MD
Prospective Study of 550 Drivers with Type 1 Diabetes — Who had Driving Mishaps and Why?
Katie Weinger, EdD, RN
Council on Behavioral Medicine and Psychology Distinguished Contributions Lecture: From Collaborations to Contributions — Advances in Behavioral Diabetes
Daniel J. Cox, PhD

Is Insulin Resistance a Relevant Treatment Target?
Clinical Assessment of Insulin Resistance
David R. Matthews, DPhil, BM, BCh
Abdominal Obesity and Other Surrogate Markers for Insulin Resistance
Mary Ann Banerji, MD
Is it Possible to Treat Insulin Resistance with Lifestyle Modification?
TBD
Is it Possible to Effectively Treat Insulin Resistance Pharmaceutically?
David M. Kendall, MD

Islet Transplantation — Improving the Process — The Islets
Receptor Mediated Promotion of Islet Viability
Marvin C. Gershengorn, MD
Overcoming Instant Blood-Mediated Inflammatory Reaction to Minimize Primary Islet Non-function
Bo Nilsson, MD, PhD
Islet Survival: Discovery of Targets by Gene Expression Profiling
Anath Shalev, MD

Islet Characterization Prior to Transplantation
Clark K. Colton, PhD

Talk Before You Act — Organ Cross-Talk in Insulin Action
Between Brain and Pancreas
Gerald J. Taborsky, Jr, PhD
Between Adipose Tissue and Muscle
Edward W. Kraegen, PhD
Between Muscle and Pancreas
Richard N. Bergman, PhD
Between Brain and Liver
Luciano Rossetti, MD

Transcriptional Effects in Insulin Signaling
LXR in Metabolic Control
Hilde Irene Nebb, PhD
Tβr Effects in Insulin Signaling
Marc R. Montminy, MD, PhD
FOXO and Insulin Signaling in Flies
Robert Tjian, PhD
c/EBP - Role in Adipogenesis
Stephen Farmer, PhD

Oral Abstract Presentations
6:30 PM - 7:30 PM
Poster Reception
MONDAY, JUNE 13
8:00 AM - 10:00 AM
Current Issues
Clinical and Pre-Clinical Updates
Predicting Type 1 Diabetes Susceptibility Using Genes and Antibodies
Ezio Bonifacio, PhD
Risk Assessment of Type 1 Diabetes — Lessons from the DPT-1
Carla J. Greenbaum, MD
Gene Therapy Approaches — How Close?
Massimo M. Trucco, MD

Symposia
A Great Little Peptide — GLP-1
Introduction and Lessons from Genetic Manipulations of the GLP-1 Receptor
Daniel J. Drucker, MD
Effects of GLP-1 on Insulin Sensitivity
Robert A. Rizza, MD
Effects of GLP-1 on Body Weight
David A. D’Alessio, MD
Therapeutic Potential of GLP-1 Analogues and DPPIV Inhibitors for Diabetes Treatment
Bo Ahrén, MD

Animal Models of Wound Healing in Diabetes
Human vs. Experimental Diabetic Wound Healing
Kelman Cohen, MD
Primates in Diabetic Models
Stephen M. Twigg, MD, PhD
Porcine Model for Wound Healing
Elof Eriksson, PhD, MD

Developmental Biology — The Beginnings of the Pancreas
Overview — Stem Cells — Insights into Development — The Path to Medical Application
TBD
Factors Regulating Adult Pancreatic Islet Growth and Function
Seung K. Kim, MD, PhD
Fishing in Pancreatic Development
Didier Stainier, PhD
Eureka! Pancreatic Revelations from the Bath Tub
Jonathan Slack, PhD

Epidemic of Impaired Fasting Glycemia — Is it Real and What Do We Do?
Who Would Be Captured in Screening for IFG?
Jacqueline Dekker, PhD

What Would Be the Impact on Health Care Delivery of Screening for IFG?
William H. Herman, MD, MPH
Would Screening for IFG Be Justified as a Public Health Policy?
Frank Vinicor, MD, MPH

Mental Health and Women’s Reproductive Health
Depression in Diabetes Before, During, and After Pregnancy
Laura J. Miller, MD
Diabetic, Pregnant and Addicted
Nada Stotland, MD, MPH
Motivating Women who have Diabetes to Plan their Pregnancies, Be Compliant with Diet, Drug Therapy, and Self-Monitoring
Denise Charron-Prochownik, PhD, MSN

The Future of PPAR Agonists
Does PPAR Alpha Play a Role in Atherogenesis?
TBD
Is PPAR Delta a Better Agonist for HDL than a CEPT Inhibitor?
TBD
What to do About Congestive Heart Failure and PPAR Treatment?
TBD

Oral Abstract Presentations
President, Health Care & Education Address
Catherine J. Tibbetts, RN, MPH, CDE
Outstanding Educator in Diabetes Award Lecture
Melinda Maryniuk, MEd, RD, CDE
Panel Discussion
The Future of DSME — Results of the NCBDE Survey
NCBDE CDE Survey Results
John F. Zrebiec, MSW, CDE
ADA’s Perspective on the Future of DSME
Carolé R. Mensing, RN, MA, CDE
AADE’s Perspective on the Future of DSME
Mary M. Austin, RD, CDE, MA
10:15 AM - 11:45 AM
Scientific Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture
Philipp E. Scherer, PhD

12:00 PM - 2:00 PM
General Poster Session
See categories listed on page 9.

12:30 PM - 1:45 PM
Council Discussion Sessions
■ Council on Pregnancy and Reproductive Health
The Top Ten Reasons We Can’t Prevent Macrosomia in GDM – Or Can We?
Linda Barbour, MD, MSPH

2:15 PM - 4:15 PM
Case Studies
■ Evolving Patterns of Diabetic Infection (Includes Roger Pecoraro Lecture)
Roger Pecoraro Lecture: The Foot in Diabetes — Pathophysiologic Basis for Clinical Care
Frank W. LoGerfo, MD
The New Diabetic Foot Infection Guidelines
Benjamin A. Lipsky, MD
Controversies in Diagnosis and Management of Osteoarthritis
Tony Berendt, BM, BCh

■ Gastric Bypass — A Quick Cure for Diabetes?
Role of Gut Hormones in Diabetes Resolution after Gastric Bypass
Randi J. Seeley, PhD
Role of the Intestinal Foregut in Diabetes Resolution after Gastric Bypass
Francesco Rubino, MD
Rapid Remission of Severe Diabetes after Roux-en-Y Gastric Bypass
Lori R. Roust, MD
Who’d have thought it? A Surgical Treatment for Diabetes
Philip R. Schauer, MD

■ How to Deal with Your Toughest Patients
Management of Patients with Hypoglycemia Unawareness
TBD
Teens and Women with Eating Disorders
Ann E. Goebel - Fabbri, PhD
Management of Diabetic Gastroenteritis
Richard McCallum, MD

Symposia
■ Exercise, Metabolic Syndrome, and Type 2 Diabetes in Youth
Type 2 Diabetes, Insulin Sensitivity, and Physical Activity in Children
Michael I. Goran, PhD
The Metabolic Syndrome in Children and its Complications
Sonia Caprio, MD
Overview of Ongoing Trials to Treat Type 2 Diabetes in Youth
Francine R. Kaufman, MD
School-Based Programs for Prevention of Obesity and Diabetes
James F. Sallis, PhD

■ Genes, Drugs and Diabetes — Pharmacogenetics of Diabetes
Lessons in Pharmacogenetics from Cardiovascular Disease and Diabetes-Related Macrovascular Complications
Donna K. Arnett, PhD, MSPH
The Emergence of Pharmacogenetics in Diabetes
Scott Taylor, PhD
Is there a Genetic Basis for Post-Transplantation Steroid-Induced Diabetes?
Alan H. Wilkinson, MD
Pharmacogenetics of Immunosuppression
Ian Hutchinson, PhD, BSc

■ Is There a Role for Glucose in Diabetic Cardiovascular Disease?
Clinical Evidence
David M. Nathan, MD
Epidemiological Evidence
Sherita H. Golden, MD, MHS

Evidence from Mouse Models
Karlin E. Bornfeldt, PhD
Evidence from Porcine Models
Ross G. Gentile, PhD

■ Motoring Along the mTOR Pathway
New Insights in mTOR Signaling
Michael N. Hall, DPhil
New Molecules in mTOR Signaling
David Sabatini, PhD, MD
Role of S6K1 in Metabolic Disease
George Thomas, PhD

Oral Abstract Presentations
4:30 PM - 6:30 PM
Case Studies
■ When Chicken Soup Fails — Emerging Treatments During Pregnancy
Lispro, Aspart, and Pumps During Pregnancy
Denice Feig, MD
Bariatric Surgery, Diabetes and Pregnancy
Eyal Sheiner, MD
DKA in Pregnancy
Guillermo E. Umpierrez, MD

Current Issues
■ Are Mice Good Models of Humans? Are Humans Bad Models of Mice?
Identification of UCP1-Independent Thermogenic Mechanisms Regulating Body Weight Using Mouse Mutants
Leslie Kozak, PhD
Regulation of Substrate Flux in the Mouse — Are Mice Just Fast Humans?
Owen McGuinness, PhD
Do You have the Right Genetic Background? Impact on Phenotypic Expression
Edward H. Leiter, PhD

■ Insulin Resistance — Fatty Acids or Circulating Factors
Circulating Factors
Mitchell Lazar, MD, PhD
Intracellular Lipid
Gerald I. Shulman, MD, PhD
Symposia
- Detection of Cardiovascular Disease in Diabetes
  Asymptomatic Ischemia in Diabetes
  Frans J. Th. Wackers, MD
  Endothelial Dysfunction in Diabetes
  Bart Staels, PhD
- Hypoglycemia in the Clinical Setting — What is Relevant and Why Does it Occur?
  How Low is Low? Defining and Reporting Hypoglycemia in Diabetes
  Philip E. Cryer, MD
  Why is Hypoglycemia Induced Glucagon Release Missing in Long-Standing Type 1 Diabetes — Evidence for the “Switch Off” Hypothesis
  R. Paul Robertson, MD
  Noninsulinoma Pancreatogenous Hypoglycemia Syndrome
  F. John Service, MD, PhD
- Obesity Treatment — Environmental and Social Influences on Behavior
  Ethnic Disparities
  Tiffany L. Gary, PhD
  Geographic Disparities
  Larry Frank, PhD
  Social Support
  TBD
  Policy
  Debra L. Haire-Joshu, PhD

Oral Abstract Presentations
Poster Discussion Session

Symposia
- New Targets for Glycemic Control
  Glycogen Phosphorylase Inhibitors
  Judith L. Treadway, PhD
  11ß-HSD1 Inhibitors to Reduce Intracellular Cortisol
  Brian R. Walker, MD
  Gluconeogenesis Inhibitors
  Marc Erion, PhD
  PTB-1B Antisense Inhibitor
  Lise Kjems, PhD
- Nutrient Modulation of Insulin Sensitivity
  PPARs and the Regulation of Glucose Homeostasis
  Sander Kersten, PhD
  Integration of Amino Acid and Insulin Signaling Through the mTOR Pathway to Mediate Translational Control of Gene Expression
  Leonard S. Jefferson, PhD
  Hexosamine Pathway Contribution to Insulin Resistance — New Insights from Muscle-specific GFAT Transgenic Mice
  Silvana Obici, MD
  AMPK as a Master Mediator of Insulin Sensitization
  Nicolas Musi, MD

TUESDAY, JUNE 14
8:00 AM - 10:00 AM
Current Issues
- Return on Investment — Is Treatment of Obesity Cost-Effective?
  Overview of Current Reimbursement
  Anne Daly, MS, RD, BC-ADM, CDE
  Reimbursement — The Payor Perspective
  Scott McFarland, JD
  The Case for Reimbursement - The Research
  Anne M. Wolf, MS, RD

Symposia
- Sleep Complications
  Epidemiology
  Richard D. Simon, Jr., MD
  How Common is Sleep Apnea in Diabetes?
  Daniel Einhorn, MD
  Does Treating Sleep Apnea in People with Diabetes Improve Metabolic Outcomes?
  Theodore Mazzone, MD
  Relationship to Diabetes and Comorbidities
  Eve Van Cauter, PhD
- The Fire within the Beta-Cell:
  Mitochondria
  The Rules of Fuels — Regulation of Mitochondrial Membrane Potential, Oxygen Consumption and Production of ROS
  David Nicholls, MD
  The Mitochondrial Genome and Respiratory Chain — Their Role in Degenerative Diseases — Implications in Diabetes
  Ann Saada Reisch, PhD
  Mitochondria — The Fuel Integrator and Processor of the Beta-Cell
  Pierre Maechler, PhD
  Back to Kennel — Revisiting the Dogma — The Fools of Rules
  Barbara E. Corkey, PhD
- The Spectrum of Micro to Macroalbuminuria — What is the Message the Kidney is Sending?
  Epidemiology of Proteinuria as a Marker of Cardiorenal Risk
  Dick de Zeeuw, MD, PhD
  Impact of Changes in Proteinuria as a Predictor of Renal Outcome
  Robert Toto, MD
  Pathophysiology of Podocyte Changes in Relation to Therapy
  Willo A. Hsueh, MD
  Optimizing Cardiorenal Outcomes
  Vivian Fonseca, MD

Oral Abstract Presentations
GENERAL INFORMATION

ABSTRACT BOOK
The Scientific Sessions Abstract Book (the June 2005 Supplement to Diabetes) will be provided free of charge at the meeting to all meeting registrants. Abstracts will also be available online two weeks before the meeting.

POSTER SESSIONS AND PRESENTATIONS
The abstracts selected as poster presentations will be displayed on Saturday, Sunday, and Monday, June 11-13, in the Exhibit Hall. Poster presenters will be at their posters for a scheduled two-hour session on one of three days of the meeting (Saturday, Sunday, or Monday). A one-hour Poster Session Reception will be held Saturday and Sunday evenings in the Poster Hall. Look for a published presentation schedule on page 9.

LOCATION AND DATES
The American Diabetes Association’s 65th Scientific Sessions and Exposition will be held at the San Diego Convention Center in San Diego, California. Sessions begin at 2:00 PM on Friday, June 10, and conclude at 10:00 AM on Tuesday, June 14.

MEETING OVERVIEW
Registration will be in the Sails Pavilion of the San Diego Convention Center. It will be open from 4:00 PM, Thursday, June 9 until 9:00 AM, Tuesday, June 14.

Program sessions will take place in the San Diego Convention Center. Session dates, times, and locations will be included with your registration materials and in the Final Program that you will receive in San Diego.

All posters will be available for viewing from Saturday, June 11 through Monday, June 13. The Poster Session hours and a complete listing of each day’s posters are listed on page 9. The exhibit hall will be open Saturday, Sunday and Monday from 10:00 AM - 4:00 PM.

CHECK OUT THE ADA 65TH SCIENTIFIC SESSIONS ONLINE AT WWW.DIABETES.ORG/AM05

The following features will be available prior to the conference:

Itinerary Planner with Abstracts — Schedule your time by creating a personalized agenda of the sessions that you plan to attend. Abstracts will be available online two weeks before the meeting.

Exhibitor Listing — Preview a current list of exhibitor names, products, and booth numbers prior to arriving in San Diego.

The following features will be available in San Diego at the Cyber Center:

Internet and E-mail Access — Retrieve or send e-mail using any web-based account. Cyber Center staff can also help you to create an account.

Message Center — Send a message to a fellow conference attendee using our secure system, or send an e-mail to your family, friends, or co-workers and receive a response via the same system.

Continuing Education Certificates — NEW THIS YEAR! Application and receipt of continuing education credit will be completed online at the meeting.

Electronic Postcards — Send an electronic message and a photo of a local San Diego attraction to friends, family, and co-workers back home.

www.diabetes.org — Visit ADA’s popular web site for the latest diabetes-related information and much more!

Visit us online at www.diabetes.org/am05
ADA CELEBRATION:
CALIFORNIA BEACH PARTY!

Saturday, June 11, 2005  
8:00 PM - 12:00 AM
Grand Ballroom  
Manchester Grand Hyatt

Join old friends and make new ones at the ADA celebration during ADA’s 65th Scientific Sessions. Celebrate San Diego. Celebrate ADA. Celebrate all of us joined together in the fight against diabetes — volunteers, researchers, healthcare providers, people with diabetes and those who care about them.

• Local band playing a mix of hits from the 50s to today — with an emphasis on beach music.
• Conga lines, line dancing, costume contests, a chance to see yourself on the big screen and other interactive ways to get you moving!
• Light snacks and a cash bar.

Dress is California casual — beachwear is a plus!

TICKETS: $25 in advance, $40 onsite
ADVANCE REGISTRATION
Register early for the 65th Scientific Sessions and take advantage of discounted registration rates. Reduced pre-registration fees are available February 26 - April 29, 2005. If you register prior to April 29, 2005, your name badge and a coupon for your meetings materials will be mailed to the address on your registration form.

HOW TO REGISTER:
Four easy ways! ONLINE, FAX, PHONE and MAIL! For accurate and easy registration:
• Register online at www.diabetes.org/am05 (This site is secure for credit card use).
• Register via fax – Complete the registration form included and fax to (972) 349-7715
• Register via phone – Call toll-free (866) 268-0195
• Register by Mail – Complete the registration form included and mail to the address listed below. If your registration cannot be postmarked by April 29, 2005, plan to register on-site. Mail the completed registration form with payment to:
  ADA Registration c/o Wyndham Jade
  P.O. Box 631737
  Baltimore, MD 21263-1737

Payments that are sent via the U.S. mail, FedEx or Overnight will require a longer processing time. Please allow a minimum of one week for delivery of domestic first class mail. Once received, your registration/reservation will be processed within 3 business days. For the fastest receipt of your confirmation, please include an e-mail address or fax number on your form.

Otherwise, allow an additional week for delivery of your confirmation via domestic first class mail. International mail may experience longer delays in receipt and delivery.

On-site Registration opens on Thursday, June 9 at 4:00 PM and continues during posted registration hours at the San Diego Convention Center. To avoid duplicate charges, please submit your registration form only once. Do not mail a registration form that you have faxed. Please type or print information clearly on the Registration Form and include a telephone number and e-mail address where you can be reached between 9:00 AM - 9:00 PM Eastern Time.

ABSTRACT PRESENTERS REGISTRATION INFORMATION
If you have submitted an abstract, or a Late-Breaking Abstract, and are waiting for notice of acceptance, you will be eligible for the early registration rate (before February 25), if your abstract is accepted. If your abstract is not accepted, and you choose not to attend the meeting, you can cancel both your meeting and hotel reservation up to June 1, 2005, with no penalty.

REGISTRATION HOURS
Registration in the San Diego Convention Center is scheduled for the days and hours listed below:

- Thursday, June 9: 4:00 PM - 8:00 PM
- Friday, June 10: 8:00 AM - 6:00 PM
- Saturday, June 11: 7:00 AM - 5:00 PM
- Sunday, June 12: 7:00 AM - 5:00 PM
- Monday, June 13: 7:00 AM - 5:00 PM
- Tuesday, June 14: 7:00 AM - 9:00 AM

CONTINUING EDUCATION HOURS
- Sunday, June 12: 7:00 AM - 5:00 PM
- Monday, June 13: 7:00 AM - 7:00 PM
- Tuesday, June 14: 7:00 AM - 11:00 AM

REGISTRATION FEES
Check the appropriate registration category and fee. If you select a one-day registration, please indicate which day.

GUEST/EXHIBIT HALL REGISTRATION
Share and experience the excitement of San Diego with your spouse or guest. Guest registration includes entrance to the exposition only. Guests are not eligible for continuing education credits. CHILDREN UNDER THE AGE OF 16 WILL NOT BE ADMITTED TO THE EXHIBIT HALL.

PAYMENT
In order to be processed, the Registration Form MUST be accompanied by payment. Acceptable forms of payment include: check (drawn on a U.S. bank in U.S. funds), or credit card (MasterCard, Visa, Discover or American Express). Checks for registration fees are payable to the American Diabetes Association, and checks for housing are payable to Wyndham Jade.

REGISTRATION REFUND POLICY
All refund requests must be submitted in writing and postmarked by May 14, 2005. Refund requests postmarked before February 25, 2005 will receive a full refund LESS a 25% processing fee. Refund requests postmarked between February 25 and May 14, 2005 will receive a registration refund LESS 50%. Refund requests postmarked after May 14 will not be honored. All refunds will be processed 30 days after the meeting concludes.

ON-SITE REGISTRATION
If your registration cannot be postmarked by April 29, 2005, plan to register on-site. Registration begins on Thursday, June 9, at 4:00 PM at the San Diego Convention Center.
Registration Form

Deadline for advance registration is April 29, 2005

All requested information must be provided to process registration.

☐ Check here if you want to receive information concerning future ADA Scientific Meetings.

The following is a list of continuing education credits to be awarded at this year’s conference. If you will be applying for credits, please check which type:

☐ Nurse ☐ Dietitian ☐ Pediatrist
☐ Physician ☐ International Physician ☐ Other, please list:
☐ Psychologist ☐ Pharmacist

1. PROFESSIONAL DEGREE

☐ MD ☐ PhD ☐ MD, PhD ☐ RN/ANP ☐ RD ☐ RPH/PharmD ☐ DO ☐ DPM

2a. I consider myself primarily: ☐ Clinician ☐ Educator ☐ Scientist ☐ Industry

2b. Are you a Certified Diabetes Educator (CDE)? ☐ Yes ☐ No

Member ID #

First Name/Given

Last Name/Family Name

Organization/Company

Street Address

City State Zip

Country (If outside the U.S., include your country/city code) E-mail

Phone Fax

3a. Choose the specialty that best describes your area of practice: (check one)

☐ Adult Endocrinology ☐ Internal Medicine ☐ Pharmacy
☐ Basic Science ☐ Nursing ☐ Podiatry
☐ Dietetics ☐ Obstetrics/Gynecology ☐ Psychology
☐ Epidemiology ☐ Ophthalmology ☐ Public Health
☐ Family Practice ☐ Pediatric Endocrinology ☐ Other

3b. Place of work: (check one)

☐ Academic ☐ Hospital ☐ Managed Care
☐ Private Practice ☐ Govt./Military
☐ Administration ☐ Corporate/Industry

3c. Special Needs. Please indicate special needs on a separate sheet and e-mail to: ada@wyndhamjade.com or mail to: Meeting Services, 1701 N. Beauregard St., Alexandria, VA 22311.

3d. In case of emergency, contact: None

_____ ( ) Day Phone

_____ ( ) Evening Phone

3e. Please indicate the ADA meetings you have attended:

☐ 03 Postgraduate ☐ 04 Postgraduate ☐ 05 Postgraduate
☐ 03 Scientific Sessions ☐ 04 Scientific Sessions

3f. PROFESSIONAL SECTION COUNCIL: (Please indicate the Council to which you belong):

☐ Behavioral Medicine & Psychology ☐ Clinical Endocrinology, Health Care Delivery and Public Health
☐ Pregnancy and Reproductive Health ☐ Diabetes in Youth
☐ Complications ☐ Epidemiology and Statistics
☐ Education ☐ Immunology, Immunogenetics and Transplantation
☐ Exercise ☐ Molecular, Cellular, & Biochemical Aspects of Diabetes
☐ Foot Care ☐ Nutritional Science & Metabolism

3b. Are you a Certified Diabetes Educator (CDE)? ☐ Yes ☐ No

Member ID #

First Name/Given

Last Name/Family Name

Organization/Company

Street Address

City State Zip

Country (If outside the U.S., include your country/city code) E-mail

Phone Fax

4. REGISTRATION FEES (Please check the appropriate fee category.)

ADA Member ☐ $350 ☐ Non Member ☐ $495 ☐ Student/Resident/Fellow ☐ $210

☐ One-Day Fee ☐ $190 ☐ $190

Indicate which day: ☐ Fri — 1/2 day ☐ Sat ☐ Sun ☐ Mon ☐ Tue

Guest ☐ $90 ☐ $90

One Guest per Full Conference Registration. Guest registration includes entrance to the Exposition and Poster Halls and Social Events only. Guests are not eligible for continuing education credit.

☐ CHILDREN UNDER THE AGE OF 16 WILL NOT BE ADMITTED TO THE EXHIBIT HALL

Guest Name

ADA Celebration: California Beach Party!

Tickets $25 in advance ($40 onsite) # Tickets ________ x $25 = $________

TOTAL payment Section 4 = $ ________

PAYMENT OF FEES

Checks/money orders for registration fees must be made payable to the American Diabetes Association in U.S. dollars, drawn on a U.S. bank.

☐ MasterCard ☐ Visa ☐ American Express ☐ Discover

Card Number Exp. Date (month/year)

Print card holder’s name

Signature Date

☐ Attendees agree to hold harmless the American Diabetes Association and the Facilities for any damages or injuries to property or individuals that may occur during the conference.

5. REGISTER

ON-LINE: For accurate and easy registration and housing, please visit us on-line at www.diabetes.org/am05

FAX your completed registration form with credit card payment to: 972-349-7715

PHONE 866-268-0195 (U.S./Canada), 972-349-5433 (International).

MAIL your completed registration form with check/money order to: ADA Registration/Housing c/o Wyndham Jade, P.O. Box 631737, Baltimore, MD 21263-1737.

OVERRIDE/FEDEX to Baltimore Lockbox Bank of America, Lockbox #631737 (Scientific Sessions), 225 N. Calvert Street, 18th Floor, Baltimore, MD 21202.

6. CANCELLATION/REFUND POLICY

All cancellation requests must be submitted in writing and postmarked on or before May 14, 2005. Cancellations postmarked before February 25, 2005, will receive a refund less a 25% processing fee. Cancellations postmarked between February 25, 2005 and May 14, 2005 will receive a refund less 50%. Cancellations postmarked after May 14, 2005 will not receive a refund. Refunds from cancellations will be processed one month after the meeting concludes.

The ADA reserves the rights to accept, reject, or condition acceptance.
TRAVEL DISCOUNTS

Travel discounts for this event have been negotiated through ADA's official travel company, MacNair Travel Management/American Express. To secure the best value to and from the meeting, as well as for any pre- or post-meeting travel plans, please contact MacNair by calling 703-836-1100 or 866-703-0395 (toll-free in the U.S., Canada or the Caribbean). Please be sure to identify yourself as an ADA meeting attendee. Discounts on our official carriers may also be secured through your local agency or the travel suppliers directly:

<table>
<thead>
<tr>
<th></th>
<th>Phone #</th>
<th>Discount #</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Airways</td>
<td>877-874-7687</td>
<td>GF16193303</td>
</tr>
<tr>
<td>United Airlines</td>
<td>800-521-4041</td>
<td>S71AU</td>
</tr>
<tr>
<td>Avis Car Rental</td>
<td>800-331-1600</td>
<td>A546499</td>
</tr>
</tbody>
</table>

TOURISM INFORMATION

Are you planning to come early or stay late? San Diego has attractions that everyone in your family, no matter what their age, will enjoy. The San Diego Convention and Visitors Bureau can provide information on attractions, theme parks, and special events to enjoy at your leisure pre- and post-convention. In addition, please use the number listed below to obtain information regarding transportation, tours, and entertainment options and general information regarding San Diego:

San Diego Convention and Visitors Bureau
619-232-3101
www.diabetes.org/am05

VISA REQUIREMENTS

In order to obtain a Letter of Invitation for your visa application you must be a fully registered (including payment) attendee for the 65th Scientific Sessions. To obtain this letter, please submit your request online at www.diabetes.org/am05, send an email request to: invitations@diabetes.org or fax a written request to: 703-683-1351. Your Letter of Invitation Request must include the following information: Registration ID number, First Name, Last Name, Street Address, City, Country and Country Codes. The letter will be mailed to the address provided unless otherwise indicated.

This invitation implies no obligation by the American Diabetes Association to cover registration fees, accommodations, travel expenses or any other costs associated with participation in this meeting. Please note that the American Diabetes Association is not able to contact U.S. Embassies on behalf of any individual attempting to gain entry into the United States to attend the 65th Scientific Sessions.

For those companies or organizations planning on sending more than one individual to the conference, please provide one Excel spreadsheet listing all individuals requesting a visa. The spreadsheet must include: Name, Passport Number, Individuals Mailing Addresses (not corporate address), City, State, Country Code and Country.

It now takes longer to receive visa approval. Please submit your Letter of Invitation request at least three weeks before you will need the letter. All Letters of Invitation are sent via USPS airmail. For security purposes, we do not email letters. If you request an expedited letter, it will be sent via FedEx. Please provide a FedEx billing account number or a credit card and expiration date for shipping charges.

Please note that this letter does not guarantee that you will be granted a visa, nor does it commit ADA to pay any expenses you may incur.

Contact Wyndham Jade, ADA’s official housing company, to make your hotel reservations. Many of ADA’s selected hotels offer the discounted meeting rate 3 days prior to the meeting and 3 days after the meeting to accommodate your extended stay.
Hotel Reservation Request Form

Reservations must be made by May 7, 2004.
To guarantee accurate hotel reservations, make sure you complete this form.

INSTRUCTIONS:
• PRINT or TYPE names of ALL people occupying the room, last name first.
• All reservation requests MUST originate through ADA Housing. If you contact hotels directly, they will advise you they are sold out, as rooms are blocked for ADA Scientific Sessions assignment through ADA Housing only.
• Reservations are taken on a first-come, first-served basis. Be sure to check the confirmation to determine which hotel ADA Housing has confirmed. The hotel may not be your first choice.
• If you require 10 or more rooms, or would like to reserve a suite, please contact ADA Housing for the appropriate housing agreement form. Phone: toll-free at 866-268-0195.
• Hotels contribute to the cost of the shuttle in order to provide value added service to their guests.

CHANGES OR CANCELLATIONS
• Reservation changes, i.e., name changes, arrival/departure revisions, and cancellations should be submitted to ADA Housing, fax: 972-349-5448, phone: toll free at 866-268-0195, or e-mail: ada@wyndhamjade.com.

DEPOSIT
• All hotels require a deposit of one night’s room and tax for each room to hold your reservation. All guarantees MUST be processed through ADA Housing. NO reservations will be made without a deposit. Your credit card may be charged for the deposit required for the hotel to which you are assigned. To receive a full refund of your deposit, cancellations must be received 7 days prior to your scheduled arrival. VISA, MasterCard, and American Express are acceptable for deposits. Checks should be made payable to Wyndham Jade/ADA.

CREDIT CARD INFORMATION

☐ VISA ☐ MasterCard ☐ American Express

Card Number Expiration Date

Name (please print)

_____________________________________________ ____________________

Signature Date

☐ Request room accessible to people with disabilities. (Please attach a separate sheet to indicate special needs).

LODGING
Please supply names of all people requesting room reservations and indicate your choice of hotel and room type. See hotel choices on next page. Please print or type. If you need to request a suite, contact ADA housing at 866-268-0195 (U.S./Canada), or 972-349-5433 (International).

<table>
<thead>
<tr>
<th>Hotel Choice #1</th>
<th>Hotel Choice #2</th>
<th>Hotel Choice #3</th>
<th>Hotel Choice #4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hotel Choice #1</td>
<td>Hotel Choice #2</td>
<td>Hotel Choice #3</td>
<td>Hotel Choice #4</td>
</tr>
</tbody>
</table>

Primary Occupant (last name first)

Share With

Share With

Share With

ON-LINE, FAX, PHONE, OR MAIL

For accurate and easy registration and housing, please visit us on-line at: www.diabetes.org/am04
or Fax: 972-349-5448
Phone: toll free at 866-268-0195 (U.S./Canada) or 972-349-5433 (International)
Mail:
Hotel Reservation Request Form
American Diabetes Association Housing
c/o Wyndham Jade
P.O. Box 678192, Dallas, TX 75267-8192
Overnight/FedEx:
Meeting Services
American Diabetes Association
1701 N. Beauregard Street
Alexandria, VA 22311

Wyndham Jade is the official housing company for ADA’s Scientific Sessions. Reservations made through any other company are not guaranteed.

The ADA reserves the right to accept, reject, or condition acceptance, based on ADA’s sole discretion, for any reason, which need not be disclosed to the applicant.

Attendees agree to hold harmless the American Diabetes Association and the Facilities for any damages or injuries to property or individuals that may occur during the conference.
<table>
<thead>
<tr>
<th>Hotel</th>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Best Western Bayside</td>
<td>$149</td>
<td>$149</td>
</tr>
<tr>
<td>2. Bristol Hotel</td>
<td>$169</td>
<td>$169</td>
</tr>
<tr>
<td>3. Comfort Inn</td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>4. Coronado Island Marriott Resort — Just added!</td>
<td>$225</td>
<td>$245</td>
</tr>
<tr>
<td>5. Courtyard Marriott Downtown</td>
<td>$180</td>
<td>$180</td>
</tr>
<tr>
<td>6. Embassy Suites</td>
<td>$199</td>
<td>$209</td>
</tr>
<tr>
<td>7. Hampton Inn Downtown</td>
<td>$149</td>
<td>$149</td>
</tr>
<tr>
<td>8. Hilton San Diego Gaslamp</td>
<td>$195</td>
<td>$195</td>
</tr>
<tr>
<td>9. Hilton San Diego Harbor Island</td>
<td>$189</td>
<td>$189</td>
</tr>
<tr>
<td>10. Holiday Inn Harbor View</td>
<td>$139</td>
<td>$139</td>
</tr>
<tr>
<td>11. Holiday Inn on the Bay</td>
<td>$179</td>
<td>$179</td>
</tr>
<tr>
<td>12. Horton Grand Hotel</td>
<td>$174</td>
<td>$174</td>
</tr>
<tr>
<td>13. Hotel Del Coronado — Just added!</td>
<td>$249</td>
<td>$249</td>
</tr>
<tr>
<td>14. Hotel Solamar — Just added!</td>
<td>$209</td>
<td>$209</td>
</tr>
<tr>
<td>15. Manchester Grand Hyatt</td>
<td>$209</td>
<td>$234</td>
</tr>
<tr>
<td>16. Marriott Gaslamp San Diego</td>
<td>$189</td>
<td>$209</td>
</tr>
<tr>
<td>17. Marriott Hotel &amp; Marina</td>
<td>CityView: $235</td>
<td>CityView: $235</td>
</tr>
<tr>
<td>18. Omni San Diego</td>
<td>$219</td>
<td>$219</td>
</tr>
<tr>
<td>19. Quality Inn &amp; Suites</td>
<td>$139</td>
<td>$139</td>
</tr>
<tr>
<td>20. Radisson Hotel Harborview</td>
<td>$145</td>
<td>$145</td>
</tr>
<tr>
<td>21. Residence Inn</td>
<td>$159</td>
<td>$159</td>
</tr>
<tr>
<td>22. Sheraton San Diego Hotel &amp; Marina</td>
<td>$199</td>
<td>$209</td>
</tr>
<tr>
<td>23. Sheraton Suites</td>
<td>$199</td>
<td>$209</td>
</tr>
<tr>
<td>24. Town &amp; Country Hotel</td>
<td>$125</td>
<td>$125</td>
</tr>
<tr>
<td>25. W Hotel</td>
<td>$232</td>
<td>$252</td>
</tr>
<tr>
<td>26. Westgate Hotel</td>
<td>$189</td>
<td>$189</td>
</tr>
<tr>
<td>27. Westin Horton Plaza</td>
<td>$220</td>
<td>$230</td>
</tr>
<tr>
<td>28. Wyndham San Diego at Emerald Plaza</td>
<td>$195</td>
<td>$195</td>
</tr>
</tbody>
</table>
The Promise of Incretin Therapies: Acute Improvement and Long-term Preservation of Islet Cell Function

Sponsored by Consensus Medical Education
Supported by an unrestricted educational grant from Novartis Pharmaceutical Corporation

Contact: Meeting Registrations, register@consensusmedical.com
Location: Marriott, Marriott Hall 1 - 3

Treatment of T2DM frequently requires multiple medications with different mechanisms of action, yet euglycemia is difficult to attain. This may be because existing therapies do not address the pathogenesis of beta-cell failure. Newer medications in late-stage clinical trials show promise of exerting novel actions on pancreatic islets, via glucagon-like peptide 1 (GLP-1). This symposium addresses these agents (including GLP-1 mimetics and DPP-4 inhibitors) that show promise for increasing insulin release and promoting both acute improvement in beta-cell function and long-term preservation of beta-cell mass and function. The role of such agents in the therapeutic armamentarium for T2DM will be explored.

Achieving Treatment Goals Combining Real-Time Glucose Sensing and Insulin Pump Therapy

Sponsored by Medtronic Minimed
Supported by an unrestricted educational grant from Medtronic MiniMed

Contact: Susan Bristol, susan.bristol@medtronic.com
Location: Omni, Grand Ballroom A - E

This program will provide participants with an evidence-based approach to diabetes management utilizing real-time continuous glucose sensing and insulin pumps to reach treatment goals.

I. Introduction
   - An evidence-based, medical approach to glucose sensing and insulin pump therapy.

II. Use of Glucose Sensing in Hypoglycemia
   - Definition/Diagnosis
   - Day-time vs. Night-time
   - Prediction and Prevention

III. Strategies for Therapy
   - Adjustments using real-time glucose sensing

IV. Reaching Treatment Targets with Sensor-Augmented Insulin Pump Therapy

V. Faculty Panel Discussion and Q&A

Clinical Experts Roundtable: Managing Cardiovascular Complexities in the Diabetic Patient

Sponsored by Medical Media Communications
Supported by an unrestricted educational grant from Merck & Co., Inc.

Contact: Barbara Rice, barbara.rice@cardinal.com
Location: Westin, California Ballroom

Diabetes mellitus doubles the risk of cardiovascular disease, even in patients with hypertension who are already at high risk because of high blood pressure. We will examine the multitude of complex conditions impacting the progression of disease in diabetic and pre-diabetic patients with hypertension. We will focus on a review of pathology, interaction of co-morbidities and current clinical evidence supporting appropriate patient management. In addition to presentations, faculty will conduct a live discussion in an effort to provide practical, evidence-based treatment strategies to minimize risk of macrovascular and microvascular complications such as myocardial infarction, stroke and nephropathy in their hypertensive patients with diabetes mellitus.

SATURDAY, JUNE 11, 2005, 5:30 am - 7:45 am

Management Strategies for the War Against Metabolic Syndrome and Type 2 Diabetes

Sponsored by ProCom
Supported by an unrestricted educational grant from GlaxoSmithKline

Contact: Lynn Rosen, rosen@commonhealth.com
Location: Marriott, Marina Ballroom D - G

Discussions with key opinion leaders have revealed a need for a program that reviews the latest clinical evidence with commentary about some of the treatment obstacles surrounding the treatment of type 2 diabetes. Insulin resistance and ß-cell impairment are core defects of type 2 diabetes, and data show that the continued impairment of ß-cell function over time results in disease progression. Outcome studies demonstrate that lowering HbA1c levels and managing co-morbidities of hypertension and dyslipidemia reduce the risk of disease complications. Therefore, an examination of the use of T2Ds, the only agents to demonstrate an effect on lowering insulin resistance, is essential to help create more positive outcomes for patients with type 2 diabetes. Faculty will present a review of current literature focusing on the identification and treatment of patients with diabetes and/or the complications of the metabolic syndrome. Some of the data presented will focus on lifestyle interventions, when to use pharmacologic interventions, and a glimpse into the future of PPARs.

How Tight is Right?: Debating the Issues of Optimal Control

Sponsored by The Institute For Medical Education
Supported by an unrestricted educational grant from Astrazeneca Pharmaceuticals LP

Contact: Pat Fitzwater, patfitwater@ime-cme.com
Location: Marriott, Marriott Hall 1 - 3

More intensive regimes for glycemic control usually require increased usage of glucose lowering medications, increasing costs and decreasing patient compliance. This has led to a debate regarding the optimal level of glycemic control as measured by the hemoglobin A1C. Current national guidelines differ in advocating A1C of 7% vs 6.5% or less. This one hour CME presentation will discuss the current guidelines in a moderated debate format, presenting evidence for and against the levels of glycemic control advocated in the current guidelines. A question and answer period will follow the debate.

Paradigm Shifts in the Management of Type 2 Diabetes: From Early Insulin Use to Novel Therapies

Sponsored by CADRE
Supported by an unrestricted educational grant from Pfizer/sanofi-aventis

Contact: Melissa Miles, mmiles@cadre-diabetes.org
Location: Marriott, Marriott Hall 4 - 6

This satellite symposium will describe changing paradigms in therapy for type 2 diabetes. The program will address practical strategies for sustaining glycemic control through early insulin use. Evidence will be presented in support of recommendations, and the discussion will provide endocrinologists and other diabetes experts with strategies for achieving sustained glycemic control through early use of insulin.

The Importance of Early Detection and Treatment of Anemia in Diabetic Patients with Chronic Kidney Disease: The Role of the Endocrinologist

Sponsored by Medical Action Communications
Supported by an unrestricted educational grant from OrthoBiotech

Contact: Stephanie Tse, stephanie.tse@quintiles.com
Location: Omni, Grand Ballroom A - E

Chronic kidney disease (CKD) is an escalating public health problem worldwide, with significant impact on patient quality of life and healthcare cost both to the individual and to society. Diabetes mellitus and hypertension are the two leading risk factors for the development of CKD. Anemia is an independent risk factor for cardiovascular disease (CVD) among high-risk patients as well as in the general population. The dramatic rise in the prevalence of chronic kidney disease (CKD) coupled with the impending shortage of nephrologists...
make it imperative for physicians from other specialties to be aware of the latest guidelines relevant to the management of CKD and its associated comorbidities (anemia, diabetes, hypertension, dyslipidemia, and bone disease). In addition, the World Health Organization estimates that the projected global prevalence of 150 million individuals with diabetes will double by 2025. This satellite symposium will help address the educational needs of endocrinologists, diabetologists, diabetes educators, nephrologists and other healthcare professionals interested in learning more about anemia and its impact on patients with CKD and CKD.

SATURDAY, JUNE 11, 2005, 5:30 pm - 9:00 pm
Beyond Glycemic Control: Novel Strategies in the Management of Diabetes
Sponsored by Scherer Clinical Communications
Supported by an unrestricted educational grant from Bristol-Myers Squibb Company
Contact: Peter Macholdt, pmacholdt@schereclin.com
Location: Marriott, Marina Ballroom D - G

Patients with diabetes develop microvascular and macrovascular disease at accelerated rates. The existence of co-morbid conditions (dyslipidemia, atherosclerosis, and other cardiovascular diseases) further exacerbates complications caused by diabetes. This program, will discuss the importance of intensive risk factor management in patients with diabetes using the most recent national guidelines for cholesterol management (ATP III), hypertension (JNC VII), and diabetes control. Participants will hear that optimal therapeutic regimens for type 2 diabetes should include the new PPAR agents, as they have been shown to reduce both hyperglycemia and hyperlipidemia. Our distinguished faculty will include James R. Gavin III, MD, PhD (Chairman), Henry N. Ginsberg, MD, and John B. Buse, MD, PhD.

Life-long Challenges of Obesity
Sponsored by Medical Media Communications
Supported by an unrestricted educational grant from Abbott Laboratories
Contact: Karin Badenhagen, kbadenhagen@medicalimedia.net
Location: Marriott, Marriott Hall 1 - 3

The prevalence of obesity in the US has more than tripled since the 1980s. The cost for not treating obesity has both clinical and financial implications. Obesity can have significant effects on morbidity and mortality, including increased risk of cardiovascular disease, dyslipidemia, and diabetes. Obesity beginning in adolescence can represent lifelong struggle for many patients. Many considerations arise with obese patients from identifying the right treatment to reimbursement issues. We hope to provide an in-depth examination of these topics in a 2-hour satellite symposium using evidence-based medicine; the goal is to better prepare physicians to better treat obese patients.

Achieving Goals in Type 2 Diabetes: The Role of Postprandial Glycemic Control
Sponsored by Liberty Communications Cardinal Health
Supported by an unrestricted educational grant from Nova Nordisk
Contact: Donna Bonuro, dbonuro@medicalcrsfire.com
Location: Marriott, Marriott Hall 4 - 6

The risk of cardiovascular disease and mortality increases with increasing postprandial blood glucose values. The Diabetes Intervention Study demonstrated that postprandial blood glucose was an independent risk factor for mortality in patients with newly diagnosed type 2 diabetes, but fasting blood glucose was not. Therefore, intervention aimed at lowering the 2h postprandial blood glucose may be important in reducing diabetic complications and mortality and may be an important focus for therapy. This trend, and current and evolving insulin analogs and technologies, has enormous potential for improving outcomes. A Medical Crossfire panel discussion/debate of these issues presents an important educational opportunity.

Prioritizing Pain: Changing Paradigms in Managing Painful Diabetic Peripheral Neuropathy
Sponsored by Current Medical Directions
Supported by an unrestricted educational grant from Pfizer Inc
Contact: Melinda Daniels, mdaniels@cmdny.com
Location: Omni, Grand Ballroom A - E

Painful diabetic peripheral neuropathy (DPN) is often viewed as a relatively minor complication of diabetes, because unlike cardiovascular disease, DPN is not life-threatening. However, the pain associated with DPN can disrupt patients’ lives in that sleep and productivity are reduced and anxiety and depression often result. This symposium will showcase the management of DPN in the context of other diabetes complications and will demonstrate the need to consider DPN a serious complication of diabetes. Current and emerging data illustrates the impact of treating DPN on quality of life and other outcomes including sleep, productivity, anxiety and depression.

Managing Sweetness and Patient Health: Scientific Straight Talk on Sugars, Sweeteners and Health
Sponsored by OldWays Preservation
Supported by an unrestricted educational grant from Coca Cola
Contact: Sara Baer-Sinnott, sara@oldwayspt.org
Location: Westin, California Ballroom

Managing Sweetness is an innovative concept to help dietary educators and advisors reach clients and consumers effectively. Managing Sweetness departs from the conventional by focusing on the inherent duality of foods and drinks: they bring us the pleasures of eating and drinking, but they also require us to manage them wisely for a life of good health. Fad diets or diets based on demonizing any one food, including sweetness and sugars, are diet plans that are doomed to fail; the issue is portion control and the concept of managing sweetness is an innovative step forward, with real potential to affect consumer behavior positively. The issue of managing sweetness is particularly important for diabetic patients and their health professionals. This seminar will introduce health professionals to the concept of managing sweetness, and in particular, how to assist diabetic patients with this concept.

SUNDAY, JUNE 12, 2005, 5:30 am - 7:45 am
Current Perspectives on the Use of Insulin in Type 2 Diabetes: Postprandial Therapy and Nonglycemic Effects
Sponsored by Thomson Interphase
Supported by an unrestricted educational grant from sanofi-aventis
Contact: Tracy Stephenson, tracy.stephenson@interphase.thomson.com
Location: Marriott, Marina Ballroom D - G

More than half of patients with type 2 diabetes who are initially treated with an oral antidiabetic agent will require additional therapies within 6 years of diagnosis to maintain fasting plasma glucose levels <6.0 mmol/L. Because a substantial proportion of these patients will eventually require insulin therapy, it is important for clinicians to understand methods by which insulin can be utilized as part of an intensive glycemic control regimen. In a number of landmark trials (Diabetes Control and Complications Trial and the UK Prospective Diabetes Study), improved glycemic control has been shown to be associated with decreased rates of microvascular complications. Because patients with diabetes vary according to their ethnicity and body mass index, clinicians should consider the possible differential effects of antidiabetic therapies. Another important topic to consider is the use of insulin in the hospital setting and the effects that intensive insulin therapy might have on outcomes. This program will focus on methods to implement intensive glycemic control with insulin therapy, investigate the role of rapid-acting insulin analogues in various patient populations, and determine methods to optimize glycemic control in the impatient setting.

Incretin Hormones in the Treatment of Type 2 Diabetes
Sponsored by The Institute for Continuing Healthcare Education
Supported by an unrestricted educational grant from Amylin Pharmaceuticals, Inc. and Eli Lilly and Company
Contact: Janet Maga, jmpaga@voxmedica.com
Pre-register Online at: http://www.dhec.org/events_gi-hormones.aspx
Location: Marriott, Marriott Hall 1 - 3

Numerous agents are currently under development to treat T2DM on the GLP-1 pathway, and the first of these may be available within the forseeable future. It is important that professionals who treat patients with T2DM become aware of the importance of GLP-1 in glucose homeostasis as well as the potential benefits and risks associated with GLP-1 mimetics, analogs, and enhancers. This symposium will detail these new agents, the scientific rationale for their use, and the results seen in clinical trials thus far.
Incidence of early stages of chronic kidney disease (CKD) is now reaching epidemic proportions, affecting over 18 million people in the United States alone. Given this increase, the optimization of glucose control through physiological approaches as well as aggressive individualized programs are warranted. Because many patients are not achieving targeted levels of glucose control, the identification of patients who fall short of goal is important. By designing treatment regimens utilizing current and novel therapies coupled with expanded understanding of insulin secretory pathophysiology, clinicians will close the gap between recommendations and results. Through authoritative debate and peer-exchange, this Medical Crossfire program conducted in conjunction with the University of Medicine and Dentistry of New Jersey, will confront these and other issues associated with novel therapies and basal plus regimens today and in the future.

**SUNDAY, JUNE 12, 2005, 6:00 pm - 10:00 pm**

**Medical Crossfire: Utilizing Novel Therapies with a Basal Plus Regimen Today and Beyond**

Sponsored by Liberty Communications Network
Supported by an unrestricted educational grant from sanofi-aventis

Contact: Greg Klobby, klobby@medicalcrossfire.com

Location: Marriott, Marina Ballroom D - G

Data continually demonstrate the increased prevalence of type 2 diabetes. Given this increase, the optimization of glucose control through physiological approaches as well as aggressive individualized programs are warranted. Because many patients are not achieving targeted levels of glucose control, the identification of patients who fall short of goal is important. By designing treatment regimens utilizing current and novel therapies coupled with expanded understanding of insulin secretory pathophysiology, clinicians will close the gap between recommendations and results. Through authoritative debate and peer-exchange, this Medical Crossfire program conducted in conjunction with the University of Medicine and Dentistry of New Jersey, will confront these and other issues associated with novel therapies and basal plus regimens today and in the future.

**Treating Hypertension in the Diabetic Patient: Bridging Clinical Data to Clinical Practice**

Sponsored by Advantage Communications, LLC
Supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation

Contact: James O’Gara, james.ogara@advantageus.com

Location: Marriott, Marriott Hall 4 - 6

Hypertension is a complex, multisystem disorder requiring integrated, strategic interventions. Due to the increased risk of cardiovascular morbidity and mortality in patients with concomitant diabetes and hypertension, it is critical that management focuses on both blood pressure reduction (i.e., achieving target BP) and preventing target organ damage. This symposium will examine the extensive data demonstrating the benefits of initial ACE inhibition in patients with diabetes, including the clinical benefits of initial ACE inhibitors/calciumpyrokinase channel blocker, fixed-dose, combination therapy.

**PPAR alpha Agonists: Mode of Action and New Trial Evidence for Their Use in Type-2 Diabetes**

Sponsored by ACCESS Medical Group
Supported by an unrestricted educational grant from Abbott Laboratories

Contact: Susan Pazderski, spazderski@access-medical.com

Location: Marriott, Marriott Hall 1 - 3

This continuing medical education program will review the use of statins, fibrates, and fibrate-statin combination therapies for the reduction of cardiovascular disease risk and mortality in patients with type 2 diabetes or the metabolic syndrome. The program will also include a presentation of pharmacokinetic data and outcomes studies that reviews the safety and efficacy of fibrate-statin combination therapy, as well as a discussion of the anti-inflammatorystatic effects of fibrates and their role in reducing atherogenesis and cardiovascular disease.

**Improving Glycemic Control in Type 2 Diabetes: A Reassessment of SMBG**

Sponsored by Health Learning Systems
Supported by an unrestricted educational grant from LifeScan, Inc.

Contact: Kathy Kramer, kkramer@commonwealth.com

Location: Westin, California Ballroom

Diabetes is associated with severe consequences and substantial costs. Postprandial hyperglycemia is emerging as a significant risk factor for cardiovascular complications, even for patients with diabetes meeting recommended A1C levels or individuals without diabetes. Tight glycemic control has been shown to avoid or delay complications of diabetes. Despite new medications and an improved understanding of diabetes, glycemic control has not improved over the last decade. New approaches to glycemic control, including improved implementation of SMBG, are warranted. National association guidelines recognize the importance of SMBG, but lack specificity regarding SMBG frequency and timing, especially in patients with type 2 diabetes. The existing evidence regarding the value of SMBG in type 2 diabetes is complicated by a paucity of randomized, controlled trials and generally low quality of observational studies. More recent, higher quality clinical studies have demonstrated the benefit of SMBG in type 2 diabetes when combined with a comprehensive educational program that informs both clinicians and patients how to use the results of SMBG testing. New approaches to improve glycemic control should include use of SMBG in all patients with diabetes as well as specific recommendations for frequency, timing, and suggested actions based on SMBG results.

**Metabolic Syndrome: The Perfect Storm in Cardiovascular Disease**

Sponsored by INNOVA Education Institute
Supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP

Contact: Mona Quinn, mquinn@cobliamededcamgroup.com

Location: Omni, Grand Ballroom A - E

In the United States, the metabolic syndrome affects 50 - 75 million people-numbers that are expected to increase dramatically, given current trends in obesity and other contributing risk factors. This symposium will address the urgent need to educate health care practitioners about (1) the substantial cardiovascular risks associated with metabolic syndrome; (2) the implications of recent NCEP-ATP III recommendations for patients with metabolic syndrome; and (3) evidence-based, aggressive lifestyle and pharmacologic interventions that can decrease cardiovascular morbidity and mortality in this patient population.

**MONDAY, JUNE 13, 2005, 5:30 am - 7:45 am**

**Inhaled Insulin: An Approach to Overcoming Patient and Physician Challenges to Glycemic Control**

Sponsored by PPS International Communications (PPSI)
Supported by an unrestricted educational grant from Global Alliance between Pfizer Inc and Aventis, a member of the sanofi-aventis Group

Contact: Leslie Laminik, llamkin@ppsiusa.com

Location: Marriott, Marina Ballroom D - G

Despite the availability of many agents to treat diabetes, glycemic control remains an elusive goal. Landmark clinical trials have shown conclusively that intensive glycemic control reduces micro- and some macrovascular complications. However, insulin often is last-resort therapy, because of patient or physician resistance to insulin use or other factors. Thus, researchers have sought safe, effective, and patient-friendly insulin delivery alternatives to pre- vent and/or delay progression of complications. One means under investigation is inhaled insulin. This program will identify challenges to provider and patient in their search for safe and effective means for glycemic control; discuss the efficacy, safety, and tolerability of pulmonary delivery of insulin.

**Beneath the Surface of DMC: Exploring the Pathophysiology of Diabetic Microvascular Complications**

Sponsored by International Medical Press
Supported by an unrestricted educational grant from Eli Lilly and Company

Contact: Katie Owrey, katie.owrey@os.imedpress.com
Pre-register Online at: http://www.caringfordiabetes.com/ada2005

Location: Marriott, Marriott Hall 1 - 3

Diabetic microvascular complications (DMC) include diabetic peripheral neuropathy, diabetic retinopathy, and diabetic nephropathy. DMC are prevalent and create heavy personal, social, economic, and healthcare resource burdens. Current recommendations for delaying development and progression of DMC emphasize frequent screening, early detection, and the use of lifestyle management and pharmacologic agents to maintain tight metabolic control. However, despite tight metabolic control, many patients still experience DMC progression. New treatments that target the underlying pathophysiology of DMC are in clinical trials and should provide more therapeutic options for DMC. In the course of this CME activity, screening guidelines for DMC and the clinical benefits...
of early DMC detection will be briefly reviewed. The program will focus on contributions of impaired metabolic states to DMC pathophysiology. Finally, current and emerging treatment options will be discussed in terms of their ability to ameliorate underlying DMC pathophysiology.

Targeting Abdominal Obesity to Reduce Cardiovascular Risk in Patients With Type 2 Diabetes

Sponsored by Discovery Institute of Medical Education
Supported by an unrestricted educational grant from sanofi-aventis
Contact: Kerry O’Rourke, kerry.orourke@dimeded.org
Location: Marriott, Marriott Hall 4

This program examines the strong association between abdominal obesity and increased metabolic and cardiovascular disease risk in patients with type 2 diabetes, specifically exploring abbreviations in metabolic and lipid parameters that occur in the presence of abdominal fat and culminate in serious comorbidities; the role of the endocannabinoid (EC) system in regulating metabolism and the pathophysiologic consequences of an EC system overstimulated in the presence of abdominal obesity; and potential use of cannabinoid CB1 antagonist to improve glycemic control and the lipid profile by reducing abdominal obesity, thus decreasing metabolic and cardiovascular disease risk in patients with type 2 diabetes.

What’s the Pancreas Been Up To? Balancing Pancreatic Hormones To Achieve Glucose Homeostasis

Sponsored by The Institute for Continuing Healthcare Education
Supported by an unrestricted educational grant from Amylin Pharmaceuticals, Inc.
Contact: Janet Moga, jmoga@voxmedico.com
Pre-register Online at: http://www.dhec.org/events_pancreatic-hormones.aspx
Location: Westin, California Ballroom

Since the 1920s, insulin has been the mainstay for controlling hyperglycemia in patients with T1DM. However, despite 80 years of refining insulin and insulin use, wide fluctuations in glycemic levels and postprandial excursions have remained common in these patients. Recent research shows that in addition to insulin, amylin - another pancreatic hormone absent in T1DM - is also important in regulating glycemia. This symposium will explore the interplay of numerous pancreatic hormones, the potential benefits of amylin supplementation in a multihormonal approach to gluco-regulation, and the implications that emerging therapeutic options may have on your clinical practice.

Admissible Evidence: Strategies for Effectively Initiating Insulin

Sponsored by Health Answers Education
Supported by an unrestricted educational grant from Novo Nordisk Pharmaceuticals
Contact: Tiffany Seltzer, tiffany.seltzer@healthanswers.com
Location: Omni, Grand Ballroom A - E

As new evidence is published it has become increasingly clear that aggressive glycemic control reduces morbidity and saves lives. As newer insulin formulations are made available strategies to manage glycemia become seemingly more complex. This program will review data demonstrating the efficacy of aggressive glycemic control and present a provocative evaluation of the prominent strategies for initiating insulin in diabetic patients in which oral antidiabetic agents are no longer appropriate. Faculty will present arguments for utilizing basal insulin, premixed analogs, and basal/bolus protocols. The program will encourage the faculty and audience to objectively evaluate the pros and cons of each strategy.

MONDAY, JUNE 13, 2005, 6:00 pm - 10:00 pm
The Emerging Role of Dual PPAR Alpha-Gamma Agonists for the Treatment of Type 2 Diabetes
Sponsored by Institute for Advanced Health Education
Supported by an unrestricted educational grant from Bristol-Myers Squibb Company
Contact: Sara Finkelstein, sfinkelstein@iahedu.org
Location: Marriott, Marina Ballroom D - G

Diabetes mellitus has become a significant multidisciplinary concern; it is associated with both microvascular and macrovascular complications and is considered a coronary heart disease risk equivalent. One therapeutic focus of diabetes management is the peroxisom-proliferator-activated receptors (PPARs), members of a nuclear receptor family which regulates glucose and lipid metabolism. Two PPARs, PPARγ and PPARα, are associated with activation by different ligands. However, a new class of agents, dual PPARα/γ agonists, activates both receptors and thus has an impact on two cardiovascular risk factors, diabetes and dyslipidemia.

Optimizing Outcomes in Patients with Diabetes and Metabolic Disease - From Evidence to Practice: Year 2005 Clinical Excellence Update
Sponsored by Thomson American Health Consultants
Supported by an unrestricted educational grant from sanofi-aventis
Contact: Stefanie Lewis, stefanie.lewis@thomson.com
Location: Marriott, Marriott Hall 1 - 3

The primary objective of this program is to provide balanced, evidence-based education to physicians on the outpatient treatment of diabetic patients with risk factors for the development of heart and renal disease, with a focus on hypertension as a primary risk factor, and the management of hypertension in patients at risk for, or with manifestations of diabetes-related renal disease. Evidence-based strategies for effective, safe, and compliance-promoting treatment of hypertension in these difficult-to-treat patient populations will be outlined, including the importance of combination therapy, per JNC-7 National Consensus Guidelines, and recommendations issued by the American Diabetes Association (ADA).

Clinical Challenges in Type 2 Diabetes and CVD: A Rapid Fire Exchange Among Experts
Sponsored by NDEI
Supported by an unrestricted educational grant from Takeda Pharmaceuticals North America
Contact: Theresa Setteducato, terri.setteducato@qwnj.thomson.com
Location: Marriott, Marriott Hall 4 - 6

Assembling a remarkable group of experts, the National Diabetes Education Initiative® symposium will include endocrinologists, cardiologists, primary care physicians, NPs, and CDEs who will discuss the management of type 2 diabetes and cardiovascular risk and prevention. As the incidence of diabetes grows a host of questions emerge: Will there be enough specialists to treat all these patients? Will PCPs and NPs take a larger role in patient care? What are the pressing economic issues in the treatment of diabetes? What treatment regimens will potentially delay the onset of cardiovascular complications in patients with type 2 diabetes?

From Point-in-time Testing to Real-Time Continuous Glucose Monitoring
Sponsored by Health Management Resources, Inc.
Supported by an unrestricted educational grant from Abbott Diabetes Care, Division of Abbott Laboratories
Contact: Christy Parke, cparke@qael.com
Location: Omni, Grand Ballroom A - E

This interactive program will utilize didactic and case studies, supported by electronic audience response technology to discuss the clinical applications of real-time continuous glucose monitoring (CGM). The program discusses the rationale behind real-time CGM and, through a series of case studies, provides opportunities to apply this technology in clinical scenarios. After attending the program, participants will be able to describe the differences between traditional point-in-time testing and CGM and develop clinical interventions based upon CGM data.

Central Dopamine Neurochemistry Influence Upon Peripheral Fuel Metabolism: Impact on Type 2 Diabetes and Obesity
Sponsored by Odyssey Pharmaceuticals, Inc.
Supported by an unrestricted educational grant from Odyssey Pharmaceuticals, Inc.
Contact: Allan Weber, allanw@odysseypharm.com
Location: Westin, California Ballroom

Evidence from several independent lines of research indicates that central dopaminergic tone plays an important role in regulating peripheral metabolism. Genetic, neuropharmacological, and neurophysiological studies from several laboratories consistently demonstrate that central dopaminergic tone is inversely correlated to rate of development of obesity, insulin resistance, and type-2 diabetes, although positively associated with central reward-feeding pathway. This symposium will review these data as well as provide available information on specific neurochemical pathways involved in dopaminergic regulation of peripheral metabolism. Finally, data from large clinical studies employing a dopamine agonist to treat type 2 diabetes will be presented.
important reasons for you to join the American Diabetes Association today!

ADA offers you the most current information about breakthroughs in diabetes research and treatment options, forums for networking with your peers, continuing education opportunities and grants that support diabetes research, turn to the American Diabetes Association (ADA). Join over 18,000 physicians, nurses, research scientists, diabetes educators and other health professionals in the Professional Section of ADA.

**ADA Members receive:**

1. **Discounts on ADA Scientific and Medical Programs** — Save up to 30% on registration fees!

2. **Up to 2 FREE Professional Section Council Memberships** — Join additional Councils for just $25 each.

3. **FREE online access to your key Journal** — Access your subscription from every office!

4. **Listing in Who’s Who in Diabetes Treatment, Education and Research Directory** — Link to a valuable network of over 18,000 diabetes experts.

5. **Professional Section Quarterly Newsletter** — Receive updates on clinical affairs, early notification of availability of new awards, updates on Recognized Programs and much more.

6. **FREE Copy of Clinical Practice Recommendations** — This extensive guide details the current ADA standards of clinical care and is an important resource for all health care professionals who treat people with diabetes.

7. **FREE key Journal Subscription** — Category I members receive a subscription to Diabetes or Diabetes Care, while Category II members receive subscriptions to Diabetes Spectrum and Diabetes Forecast. Members who want to subscribe to additional journals will receive special members-only discounted rates.

   - *Diabetes*® — the world’s most-cited peer-reviewed journal of original diabetes research brings you the latest findings from the world’s top scientists. In print and online
   - *Diabetes Care*® — the premier peer-reviewed journal of original diabetes research and treatment publishes findings from clinical research, human and animal trials. In print and online
   - *Diabetes Spectrum*® — translates research into practice for nurses, dietitians and other health care professionals involved in patient education and counseling. In print and online
   - *Clinical Diabetes*® — for the primary-care provider as well as other diabetes specialists, Clinical Diabetes offers articles and abstracts highlighting recent advances in diabetes treatment. In print and online
   - *Diabetes Forecast*® — a valuable tool for patient education, ADA’s magazine for patients and their families features advice on diet, exercise and other lifestyle changes. Print only

8. **Members-Only Discounts on ADA Periodicals, Books and Patient Materials** — ADA also publishes diabetes education books, pamphlets, videotapes and CD ROMs. ADA members receive automatic discounts on most items.

**Additional Opportunities…**

- **ADA Research Grants and Awards** — All qualified professionals can apply for available research grants and awards.

- **Local Involvement** — You can participate in patient and professional education programs, network with other professionals and actively shape the future of ADA.

---

**Ready to Join?**

To enroll, complete the application, enclose your membership dues, and mail or fax it to us at the address below. We’ll send you a Professional Membership Welcome Package that includes the latest Who’s Who in Diabetes directory and a member certificate suitable for framing. Fax or mail your application today:

**ADA Professional Section**
P.O. Box 631762
Baltimore, MD 21263-1762
(703) 549-1500, ext. 2343
Fax (703) 549-6995
http://www.diabetes.org

**ADA**

*Cure, Care, Commitment*
JOIN ADA Today
Mail with payment to ADA, Professional Section, PO Box 631762, Baltimore, MD 21263-1762

1. Name: ____________________________ Email: ____________________ (council communications are via email)
   Address: __________________________ Phone: ____________________ Fax: ____________________
   City __________________ State ______ Zip ______ Country __________ Degrees _______ / _______ / __________

2. Primary Area of Focus:  □ Clinical Practice □ Research □ Education □ Industry

3. Choose Your Membership Category
   Category I: Please note, Physicians must join this category
   - Domestic Members: $220
   - Overseas Members: $285
   - Domestic in Training Dues: $110
   - Overseas in Training Dues: $175
   - Diabetes* (monthly): Basic research on the pathophysiology of diabetes.
   - Diabetes Care* (monthly): Clinical care and research.
   - Dues:
     - Domestic Members: $110
     - Overseas Members: $158
     - Domestic in Training Dues: $55
     - Overseas in Training Dues: $80
   - Journals (includes journals listed below):
     - Diabetes Forecast* (monthly): Lifestyle magazine for patients and their families.

4. Order Additional Publications at “Members-only” Rates: North America/International Rates
   - Diabetes Care (monthly) $157/$229
   - Diabetes Spectrum (quarterly) $40/$61
   - Diabetes Forecast (monthly) $157/$229
   - Diabetes (monthly) $157/$229
   - Diabetes Spectrum (monthly) $50/$50
   - Diabetes Forecast (monthly) $14/$44/$77.08/$62
   - All journals include online subscription, except Diabetes Forecast

5. Select up to TWO FREE Council Memberships:
   Extra Council Memberships are $25 each.
   - PS AD Administration
   - PS BC Biochemistry
   - PS CA Cardiology
   - PS DE Dermatology
   - PS DO Dentistry
   - PS ED Education
   - PS EN Adult Endocrinology
   - PS EP Epidemiology
   - PS EX Exercise Physiology
   - PS FP Family Practice
   - PS GE Geriatrics
   - PS GP General Practice
   - PS GT Genetics
   - PS IM Internal Medicine
   P S IU Immunology
   P S ME Metabolism
   P S NE Nephrology
   P S NR Neurology
   P S NS Nursing
   P S NU Nutrition
   P S OG Obstetrics/Gyn.
   P S OP Ophthalmology
   P S OR Orthopedics
   P S OS Osteopathy
   P S OT Optometry
   P S PA Pharmacology
   P S PC Psychology
   P S PE Pediatrics

6. Mark Your Primary Work Setting:
   - University/Academic (1)
   - Private/Group Practice (2)
   - Hospital (3)
   - HMO (4)
   - Public Health (5)
   - Government (7)
   - Pharmacy (8)
   - Pharmaceutical/Manufacturing (9)
   - Nursing Home (10)
   - Home Health (11)

7. Circle one Primary (P) and one Secondary (S) Specialty
   - PS AD Administration
   - PS BC Biochemistry
   - PS CA Cardiology
   - PS DE Dermatology
   - PS DO Dentistry
   - PS ED Education
   - PS EN Adult Endocrinology
   - PS EP Epidemiology
   - PS EX Exercise Physiology
   - PS FP Family Practice
   - PS GE Geriatrics
   - PS GP General Practice
   - PS GT Genetics
   - PS IM Internal Medicine
   - PS IU Immunology
   - PS ME Metabolism
   - PS NE Nephrology
   - PS NR Neurology
   - PS NS Nursing
   - PS NU Nutrition
   - PS OG Obstetrics/Gyn.
   - PS OP Ophthalmology
   - PS OR Orthopedics
   - PS OS Osteopathy
   - PS OT Optometry
   - PS PA Pharmacology
   - PS PC Psychology
   - PS PE Pediatrics

8. Enclose Payment and Mail Today!
   - □ New Membership or □ Renewing Membership
   - □ Dues:
     - Category I $ _______ or Category II $ _______
     - Additional Subscriptions: $ _______
     - Additional Councils: _______ x $25 = $ _______
     - Taxes: Canadians must add 7% GST tax $ _______
     - TOTAL ENCLOSED: $ _______
   - □ Check payable to the American Diabetes Association
   - Account No.: ____________________
   - Expiration Date: ____________________
   - Date: _______ Signature: ____________________

FOR FAST SERVICE—Send a fax to our membership department:
Fax: (703) 549-6905
Phone: (703) 549-1500, ext. 2343

Allow 4-6 weeks to process your order. Price limits subject to change. Payment must accompany order in US funds drawn on US bank. Price effective through June 30, 2005.

Dues amount set aside for publication are:
- □ Category I (Diabetes or Diabetes Care): $100 Dom/$160 Intl
- □ Category II (Diabetes Spectrum): $50 Dom/$50 Intl

Diabetes Forecast: $14 Dom/$45 Intl

Please fax or mail only one copy of your order to avoid duplication.